<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>12517732
    </Internal_Number>
    <TrialID>ISRCTN24711056
    </TrialID>
    <Last_Refreshed_on>5 September 2022
    </Last_Refreshed_on>
    <Public_title>Implementation of WHO-endorsed technologies for TB diagnosis in Africa: opportunities, strengths and challenges
    </Public_title>
    <Scientific_title>Roll-out and scale-up of WHO-endorsed technologies for TB diagnosis in Africa: opportunities, strengths and challenges                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Makerere University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220823
    </Date_registration3>
    <Date_registration>23/08/2022
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN24711056
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>20/07/2022
    </Date_enrollement>
    <Target_size>188
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational study (cross-sectional study) (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Algeria;Angola;Anguilla;Burkina Faso;Burundi;Cameroon;Uganda;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Adults aged 18 years and above who occupy the position of managers of the National TB Programme, National TB Reference Laboratories and Partners
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Participants who do not consent to respond to the survey questionnaire&lt;br&gt;                2. Those who are in position for less than a year&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Tuberculosis &lt;br&gt;Respiratory
    </Condition>
    <Intervention>There will be a focus on the uptake, utilization, roll-out, implementation, adoption and the operationalization of WHO-TB diagnostic technologies upon endorsement by the World Health Organization followed by the implementation at country levels, between 2007 and 2017 (up to 2021). Predisposing, enabling and need factors influencing rapid uptake of WHO-endorsed TB diagnostic technologies will be collected though a survey questionnaire sent to the Heads of the National Tuberculosis Programme, National TB Reference Laboratory Managers and partners in 47 countries in Africa. Participants will be required to consent and respond to different questions. Systematic reviews and meta-analysis of studies published between 2007 and 2017 at country level in Africa will inform how stakeholder awareness, predisposing and need factors are related to uptake, access and utilization. An "easy to use tool” will be developed and disseminated by email to selected countries (slow implementers, where the uptake has been identified as poor) as a guide for a better implementation.
    </Intervention>
    <Primary_outcome>We will analyze responses by classifying countries into categories (scoring from 0 to 5). Rapid implementers will have a score of 5 if the specified technology shows its implementation occurred within 1 to 3 years after WHO endorsement, moderate implementers will be from 3 to 5 years and slow implementers will be countries that show implementation after 5 years onward following the WHO endorsement. Gaps on diagnostic part per countries will be highlighted as an impediment to notification of TB cases and enabling factors (funding, leadership,...) will be developed to better guide countries in improving their uptake. We will document threats and opportunities (from field experience) including good practices from TB laboratory services contribution to support recent emergency disease outbreaks in Africa and identify areas where integration of TB diagnostic platforms can serve other disease programmes.
    </Primary_outcome>
    <Secondary_outcome>There are no secondary outcome measures
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Nil known
    </Secondary_ID>
    <Source_Support>Makere University
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 20/07/2022, Makerere University, College of Health Sciences, School of Biomedical Sciences Research Ethics Committee (SBSREC, P.O. Box 7072 Kampala, Uganda; +256 779340363; uncstresearch@uncst.go.ug), ref: 1.0, 2022-07-19
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>19/06/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>11713945
    </Internal_Number>
    <TrialID>NCT05136105
    </TrialID>
    <Last_Refreshed_on>6 December 2021
    </Last_Refreshed_on>
    <Public_title>Preventing Trauma Symptoms in the Aftermath of Sexual Abuse in Children and Adolescents in Burundi
    </Public_title>
    <Scientific_title>Preventing Trauma Symptoms in the Aftermath of Sexual Abuse in Children and Adolescents in Burundi
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211112
    </Date_registration3>
    <Date_registration>12/11/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05136105
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 10, 2021
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burundi
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Anselm Crombach, Dr.;Manassé Bambonyé, Dr.
    </Contact_Lastname>
    <Contact_Email>anselm.crombach@uni-konstanz.de;m.bambonye@psf-burundi.org
    </Contact_Email>
    <Contact_Tel>+491793287291;+25775458006
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Sexual abuse within the past month&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants are recruited when they approach a first aid center for survivors of&#x0D;&lt;br&gt;             sexual abuse&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive disability&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of mind altering drugs&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Posttraumatic Stress Disorder;Mental Health Issue;Family Dynamics
    </Condition>
    <Intervention>Behavioral: Preventive Narrative Exposure Therapy (PreNET) family intervention
    </Intervention>
    <Primary_outcome>1. Change in mental health measured via the Strengths and Difficulties Questionnaire (SDQ);2. Change in PTSD symptom severity measured via the University of California in Los Angeles(UCLA)-PTSD Reaction Index
    </Primary_outcome>
    <Secondary_outcome>3. Change in abuse-related parental acceptance-rejection
    </Secondary_outcome>
    <Secondary_ID>UKAC2021
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>12517828
    </Internal_Number>
    <TrialID>ISRCTN45167024
    </TrialID>
    <Last_Refreshed_on>5 September 2022
    </Last_Refreshed_on>
    <Public_title>Eczema monitoring online via questionnaires
    </Public_title>
    <Scientific_title>Evaluation of the effect of symptom monitoring with patient-reported outcome measures on clinical outcomes in eczema: an online, parallel-group randomised controlled trial (EMO trial)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>University of Nottingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210629
    </Date_registration3>
    <Date_registration>29/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN45167024
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>14/09/2021
    </Date_enrollement>
    <Target_size>266
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Online parallel-group randomized controlled clinical trial (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Self-report or parent/carer report of eczema diagnosis by a healthcare professional&lt;br&gt;                2. Person aged 1 year or older&lt;br&gt;                3. Able and willing to provide informed consent&lt;br&gt;                4. If under 16 years old, a parent/carer needs to provide informed consent on behalf of the child&lt;br&gt;                5. Able to read and understand written English&lt;br&gt;                6. Have access to the internet and to an internet-enabled device&lt;br&gt;                7. POEM score of 3 or above at eligibility screening&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Unable/unwilling to provide informed consent&lt;br&gt;                2. Currently taking part in another eczema clinical trial&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Eczema &lt;br&gt;Skin and Connective Tissue Diseases &lt;br&gt;Dermatitis and eczema
    </Condition>
    <Intervention>This is a methodological trial and there will be no treatment intervention involved. The intervention will be the online Patient Oriented Eczema Measure (POEM) questionnaire. Eligible participants will be randomised online and assigned to either the intervention group or to the control group using the REDCap software. The randomisation schedule will be based on computer-generated codes using random permuted blocks of varying size, stratified by age and baseline disease severity. The PhD student will deal with participant queries, thus she will have access to group allocation, but the other trial team members and the trial statistician will remain blinded. Participants in the intervention group (weekly group) will be asked to complete the POEM questionnaire weekly for 8 weeks. The control group will not receive the intervention.
    </Intervention>
    <Primary_outcome>Eczema severity measured by the self-reported or proxy (parent/carer reported) POEM questionnaire score at baseline and 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Adherence to eczema treatment use, assessed in two ways:&lt;br&gt;                1.1. Eczema treatment use assessed by the emollient and topical corticosteroid use questionnaire over the last week from baseline to 8 weeks&lt;br&gt;                1.2. Eczema treatment use assessed by the overall eczema treatment use questionnaire 2 months prior to joining the study and at the end of the study at 8 weeks&lt;br&gt;                2. Missing data: the proportion of fully completed questionnaires at 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;EMO 120421
    </Secondary_ID>
    <Source_Support>University of Nottingham
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 23/04/2021, Faculty of Medicine &amp; Health Science Research Ethics Committee, University of Nottingham (Faculty Hub, Room E41, E Floor, Medical School, Queen's Medical Centre Campus, Nottingham University Hospitals, Nottingham, NG7 2UH, UK; +44 (0) 115 74 85060; FMHS-ResearchEthics@nottingham.ac.uk), ref: 239-0421
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>03/04/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>12373275
    </Internal_Number>
    <TrialID>ISRCTN12329547
    </TrialID>
    <Last_Refreshed_on>27 June 2022
    </Last_Refreshed_on>
    <Public_title>Trial of a digital depression management application: juli
    </Public_title>
    <Scientific_title>Randomised control trial of a digital depression management application: juli                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210608
    </Date_registration3>
    <Date_registration>08/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN12329547
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>21/06/2021
    </Date_enrollement>
    <Target_size>476
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional placebo-controlled randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary
    </Countries>
    <Contact_Firstname>Bettina
    </Contact_Firstname>
    <Contact_Lastname>Dührkoop
    </Contact_Lastname>
    <Contact_Address>
                    Juli Health
                    23 Beach Ave
                
    </Contact_Address>
    <Contact_Email>bd@juli.co
    </Contact_Email>
    <Contact_Tel>+44 (0)20 7679 9736
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Depression with PHQ-8 score &gt;4 at baseline&lt;br&gt;                2. Age 18 to 65 years (inclusive)&lt;br&gt;                3. English speakers&lt;br&gt;                4. Have an iPhone&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. PHQ-8 &lt;5 at baseline&lt;br&gt;                2. Children&lt;br&gt;                3. Non-English speakers&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Depression &lt;br&gt;Mental and Behavioural Disorders &lt;br&gt;Depressive episode, unspecified
    </Condition>
    <Intervention>&lt;br&gt;                Participants will be randomly allocated using an online tool to receive the juli app or treatment as usual plus an attention placebo control app.&lt;br&gt;&lt;br&gt;                The participant will use the juli app for 8 weeks and complete a depression symptoms questionnaire every 2 weeks (four in total). Participants will also be asked to complete a wellbeing questionnaire at 4 and 8 weeks and a user satisfaction questionnaire at 8 weeks. These are all standardised questionnaires, commonly used for research (the 8-item Patient Health Questionnaire, the 12-item Short Form survey of health-related quality of life and the Mobile Health App Usability Questionnaire).&lt;br&gt;&lt;br&gt;                The full version of the app presents the participant with graphical displays of some data automatically generated from their phone and smartwatch. The types of data are:&lt;br&gt;                1. Sleep – time in bed and time asleep&lt;br&gt;                2. Activity – steps and flights of stairs climbed&lt;br&gt;                3. Heart rate variability – the variation in the time interval between heartbeats&lt;br&gt;                4. Workouts – periods of exercise&lt;br&gt;                5. Oxygen saturation&lt;br&gt;                6. Menstrual cycle&lt;br&gt;&lt;br&gt;                It also presents them with external data: weather, pollen count and air quality (provided via geolocation). It asks the participant to rate how they are feeling and answer questions about their mood on a daily basis. It allows them to set a medication reminder, and add notes to a journal. It presents them with correlations between these different types of data and helps them to identify things that make their mood better or worse.&lt;br&gt;&lt;br&gt;                Participants allocated to the dummy version of the app will be asked to rate how they are feeling on a daily basis, but will not
    </Intervention>
    <Primary_outcome>Depression symptoms measured using the eight-item Patient Health Questionnaire (PHQ-8) at 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Depression symptoms measured using the PHQ-8 at 2, 4 and 6 weeks&lt;br&gt;                2. Health-related quality of life measured using Short Form 12 (SF-12) Item at 4 and 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known
    </Secondary_ID>
    <Source_Support>Juli Health
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 07/06/2021, UCL Research Ethics Committee (Office of the Vice-Provost (Research), University College London, 2 Taviton St, London, WC1E 6BT, UK; +44 (0)20 7679 8717; ethics@ucl.ac.uk), ref: 19413/001
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/08/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>12373274
    </Internal_Number>
    <TrialID>ISRCTN87679686
    </TrialID>
    <Last_Refreshed_on>27 June 2022
    </Last_Refreshed_on>
    <Public_title>Trial of a digital asthma management application: juli
    </Public_title>
    <Scientific_title>Randomised controlled trial of a digital asthma management application: juli                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210608
    </Date_registration3>
    <Date_registration>08/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN87679686
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>21/06/2021
    </Date_enrollement>
    <Target_size>180
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional placebo-controlled randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Bettina
    </Contact_Firstname>
    <Contact_Lastname>Dührkoop
    </Contact_Lastname>
    <Contact_Address>
                    juli Health
                    23 Beach Ave
                
    </Contact_Address>
    <Contact_Email>bd@juli.co
    </Contact_Email>
    <Contact_Tel>+44 (0)20 7679 9736
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Asthma with Asthma Control Test score&lt;20 at baseline&lt;br&gt;                2. Age 18 to 65 (inclusive)&lt;br&gt;                3. English speaker&lt;br&gt;                4. Have an iPhone&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Asthma Control Test&gt;19 at baseline&lt;br&gt;                2. Children&lt;br&gt;                3. Non-English speakers&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Reduction of asthma symptoms in adults with asthma &lt;br&gt;Respiratory &lt;br&gt;Asthma
    </Condition>
    <Intervention>&lt;br&gt;                Use of juli app vs treatment as usual (plus attention placebo control app).&lt;br&gt;&lt;br&gt;                juli app: Participants will be prompted to open the app each day via an automated alert. They will be asked to rate how they are feeling on a scale using 5 emojis and track number of shortness of breath episodes, rescue inhaler usage and night time waking with shortness of breath. The app will gather information via Apple HealthKit; sleep, activity, workouts, oxygen saturation. It will present this data to the participant and show associations with asthma symptoms. It will make recommendations about these parameters to guide healthy behaviours and will use external data sources (weather, air quality, pollen count) to guide these recommendations. The app has a medication reminder function that can be set by the participants to improve medication adherence. Participants are also encouraged to engage in journaling via the app, especially in relation to exacerbating or reliving factors for asthma symptoms.&lt;br&gt;&lt;br&gt;                Attention placebo control app: Participants will be prompted to open the app each day via an automated alert and rate how they are feeling on a scale using 5 emojis.&lt;br&gt;&lt;br&gt;                The participant will use the app for eight weeks and complete an asthma questionnaire every two weeks (four in total). Participants will also be asked to complete a well-being questionnaire at four and eight weeks and a user satisfaction questionnaire at eight weeks.&lt;br&gt;
    </Intervention>
    <Primary_outcome>Asthma symptoms measured using the Asthma Control Test at 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Asthma symptoms measured using the Asthma Control Test at 2, 4, and 6 weeks&lt;br&gt;                2. Short Form 12 Item health-related quality of life at 4 and 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Nil known
    </Secondary_ID>
    <Source_Support>juli Health
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 07/06/2021, UCL Research Ethics (Office of the Vice-Provost (Research), University College London, 2 Taviton St, London, WC1E 6BT, UK; +44 (0)20 7679 8717; ethics@ucl.ac.uk), ref: 19413/001
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/08/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>10750449
    </Internal_Number>
    <TrialID>ISRCTN56646695
    </TrialID>
    <Last_Refreshed_on>22 March 2021
    </Last_Refreshed_on>
    <Public_title>Integrating self-affirmation content into a smoking cessation mobile app
    </Public_title>
    <Scientific_title>Integrating the use of self-affirmation content into a mobile app to promote quit attempts with text-based smoking cessation intervention messaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>National Cancer Institute
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210212
    </Date_registration3>
    <Date_registration>12/02/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN56646695
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>07/03/2018
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized 2 x 2 factorial design (integrated affirmation: affirmation texts present versus absent; baseline affirmation: questionnaire present versus absent) (Prevention)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Elizabeth
    </Contact_Firstname>
    <Contact_Lastname>Seaman
    </Contact_Lastname>
    <Contact_Address>600 Peachtree St NE #1000
    </Contact_Address>
    <Contact_Email>eseaman@cdcfoundation.org
    </Contact_Email>
    <Contact_Tel>+1 (0)4438524139
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                A randomly selected proportion of users who downloaded the free version of the Smoke Free-Quit Smoking Now mobile application during the study period (initially 10% and then increased to 30% to achieve recruitment goals) are shown a consent form and invited to participate in this study. Once participants who opted in completed the baseline assessment, their eligibility was determined. In order to participate, app users had to be:&lt;br&gt;                1. Adults (between the ages of 18-98)&lt;br&gt;                2. Selected a cessation date after the day they downloaded the app but not more than 14 days in the future&lt;br&gt;                3. Completed the baseline assessment&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Under 18 years or over 98 years old&lt;br&gt;                2. Selected a quit date more than 14 days in the future or more than 1 day in the past&lt;br&gt;                3. Paid for additional app features (Pro users)&lt;br&gt;                4. Did not complete the baseline assessment&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Smoking cessation among current smokers &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>Two types of self-affirmation inductions (Integrated, Baseline) were added to a publicly available smoking cessation mobile application (Smoke-Free Quit Smoking Now). All users who met the inclusion criteria, provided consent to participate and completed a baseline assessment, were randomized to 1 of 4 conditions. Half of the participants were randomly assigned to complete a self-affirmation induction upon study entry. Orthogonally, half of the participants were randomly assigned to receive self-affirming text notifications during their quit attempt or to receive conventional notifications. The induction and the text notifications were fully automated, and all data were collected through self-assessments in the mobile application. Self-reported smoking cessation was assessed 1 month and 3 months following study entry.
    </Intervention>
    <Primary_outcome>Smoking cessation measured through self-assessments in the mobile application: past-week cessation at 1 month, past-month cessation at 1 month, past-week cessation at 3 months, and past-month cessation at 3 months
    </Primary_outcome>
    <Secondary_outcome>Optimism and baseline mood states (happiness, anger, anxiousness, hopefulness, sadness) measured through self-assessments in the mobile application at baseline 
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;17CN039
    </Secondary_ID>
    <Source_Support>National Cancer Institute
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 12/04/2018, the National Institutes of Health Intramural Institutional Review Board (Office of Human Subjects Research Protections, 6700B Rockledge Drive, Suite 4300, Bethesda, MD 20817, USA; +1 301 402 3713; irb@od.nih.gov), ref: #17CN039
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>06/03/2019
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>10420986
    </Internal_Number>
    <TrialID>ISRCTN95140761
    </TrialID>
    <Last_Refreshed_on>5 January 2021
    </Last_Refreshed_on>
    <Public_title>An international study to investigate rates of death and illness following surgery of the pancreas
    </Public_title>
    <Scientific_title>International Pancreatic Surgery Outcomes Study - PancreasGroup.org                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Royal Free London NHS Foundation Trust
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201203
    </Date_registration3>
    <Date_registration>03/12/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN95140761
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2021
    </Date_enrollement>
    <Target_size>3500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational cohort study (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United States Minor Outlying Islands;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Adults 18 years of age or older&lt;br&gt;                2. All indications (including benign and malignant)&lt;br&gt;                3. Open, laparoscopic or robotic&lt;br&gt;                4. Elective or emergency&lt;br&gt;                5. Partial or total pancreatectomies&lt;br&gt;                6. Pancreatic tumour enucleations&lt;br&gt;                7. Procedures with concomitant vascular or other organ resections&lt;br&gt;                8. Pancreatic duct drainage procedures (e.g. Frey, Puestow, or Beger)&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Pancreas or islet cell transplantation&lt;br&gt;                2. Transcutaneous or transgastric imaging-guided ablation (e.g. RFA) or electroporation (e.g. NanoKnife)&lt;br&gt;                3. Endoscopic (e.g. ERCP, stent or lithotripsy) procedures&lt;br&gt;                4. Endoscopic transgastric and surgical necrosectomies&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Patients with pancreatic disease requiring surgery &lt;br&gt;Surgery
    </Condition>
    <Intervention>Participants, agreeing to be part of this study, will be observed from the date of surgery until hospital discharge as well as 90 days after their operation. Fully anonymised data will be collected including the participant, their disease, operation characteristics as well as outcomes, such as events including death and illness.
    </Intervention>
    <Primary_outcome>Mortality rate 90 days postoperatively measured using patient records
    </Primary_outcome>
    <Secondary_outcome>Morbidity as defined by the Clavien-Dindo Classification and measured by the Comprehensive Complications Index ® (CCI®) at 90 days postoperatively measured using patient records
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;RFH287_20-21
    </Secondary_ID>
    <Source_Support>Royal Free Charity - Fiorina Fund
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>No ethics approval required. Registered and approved as an audit by the Royal Free Hospital Quality Governance Department with the ID number RFH287_20-21
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/03/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>12635176
    </Internal_Number>
    <TrialID>ISRCTN13539303
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>An international registry of coronavirus exposure in pregnancy
    </Public_title>
    <Scientific_title>International Registry of Coronavirus Exposure in Pregnancy (IRCEP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Pregistry LLC
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201030
    </Date_registration3>
    <Date_registration>30/10/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN13539303
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>08/06/2020
    </Date_enrollement>
    <Target_size>25000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Prospective observational study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan
    </Countries>
    <Contact_Firstname>Diego;Sonia
    </Contact_Firstname>
    <Contact_Lastname>Wyszynski;Hernandez-Diaz
    </Contact_Lastname>
    <Contact_Address>
                    1801 Century Park East
                    25th Floor
                ;677 Huntington Avenue
    </Contact_Address>
    <Contact_Email>hello@pregistry.com;shernan@hsph.harvard.edu
    </Contact_Email>
    <Contact_Tel>+1 (747) 200-5468;+1 (617) 432-3942
    </Contact_Tel>
    <Contact_Affiliation>;
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Adult pregnant women with clinical confirmation of COVID-19 or tested for SARS-CoV-2 at any time during their pregnancy
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Subjects who do not meet the inclusion criteria
    </Exclusion_Criteria>
    <Condition>COVID-19 (SARS-CoV-2 infection) during pregnancy &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)
    </Condition>
    <Intervention>&lt;br&gt;                The IRCEP will be an observational cohort study with prospective and retrospective components. Registration and participation via website or mobile app specially developed for the IRCEP will be voluntary. Women 18 years of age and older will be encouraged to enrol if at any time during pregnancy, they had a test performed for the coronavirus (regardless of the result) or if they had clinical confirmation of COVID-19 in the absence of a SARS-CoV-2 test. Women with confirmed COVID-19 via clinical or test methods will be included in the exposed group and women with a negative test will be included in the control group. Eligible women will be able to enrol at any time during gestation. Given the public health emergency due to the COVID-19 pandemic and the urgent need for data, the IRCEP will also enrol eligible women retrospectively during the first 180 days after delivery (if they delivered after December 2019).&lt;br&gt;&lt;br&gt;                As numbers accumulate, the natural history of COVID-19 during pregnancy will be reported stratified by days since COVID-19 confirmation at enrollment (i.e., from prospective if immediate to retrospective if enrolled after resolution) and the risk of pregnancy outcomes by COVID-19 exposure group will be reported stratified by trimester at enrollment. For the assessment of miscarriages, only participants enrolled during the first trimester will be included and the analyses will be stratified by gestational week at enrollment. For other outcomes, the primary analysis will include all enrollees. However, sensitivity analyses of 1) teratogenicity will be restricted to participants enrolled before an informative prenatal screening was done; 2) late-pregnancy outcomes (e.g. preeclampsia) will be restricted to participants enrolled before 
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Measured by maternal self-report using online questionnaire at baseline:&lt;br&gt;                1. Pregnancy outcomes:&lt;br&gt;                1.1. Miscarriage (or spontaneous abortion)&lt;br&gt;                1.2. Elective termination&lt;br&gt;                1.3. Stillbirth&lt;br&gt;                1.4. Preterm delivery&lt;br&gt;                2. Birth outcomes (measured at additional time points up to 90 days):&lt;br&gt;                2.1. Major structural defects&lt;br&gt;                2.2. Neonatal death&lt;br&gt;                2.3. Admission into the Neonatal Intensive Care Unit&lt;br&gt;                2.4. Maternal obstetric complications&lt;br&gt;                2.5. Post-partum health&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Measured by maternal self-report using online questionnaire:&lt;br&gt;                1. Head circumference (cm) at each time point from baseline to 90 days.&lt;br&gt;                2. Length at birth (cm)&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>NCT04366986;Nil known
    </Secondary_ID>
    <Source_Support>Pregistry LLC
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 08/06/2020, Institutional Review Board (IRB) of the Harvard T.H. Chan School of Public Health (90 Smith Street, 3rd Floor Boston, MA 02120, USA; +1 (617) 432-5132; kninsala@hsph.harvard.edu), ref: # IRB20-0622
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/04/2024
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>12530559
    </Internal_Number>
    <TrialID>ISRCTN85785540
    </TrialID>
    <Last_Refreshed_on>12 September 2022
    </Last_Refreshed_on>
    <Public_title>Evaluating an app to help people quit smoking
    </Public_title>
    <Scientific_title>Effectiveness of an offer of the Smoke Free smartphone application for smoking cessation compared with no support: the App for Smoking ceSsation Evaluation Trial (ASSET)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201015
    </Date_registration3>
    <Date_registration>15/10/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN85785540
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>20/08/2020
    </Date_enrollement>
    <Target_size>3116
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Aged at least 18 years&lt;br&gt;                2. Able to provide consent&lt;br&gt;                3. English speaker&lt;br&gt;                4. Owns a smartphone&lt;br&gt;                5. Current cigarette smoker&lt;br&gt;                6. Willing to be followed-up by e-mail and complete online questionnaires after 1, 4 and 30 weeks&lt;br&gt;                7. Interested in making a quit attempt within the next month&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Used the Smoke Free app in the past 6 months
    </Exclusion_Criteria>
    <Condition>Smoking cessation &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>&lt;br&gt;                This will be a two-arm individually randomized controlled effectiveness trial. Participants will be adult smokers who are intending to quit in the next 4 weeks, willing to participate in a 30-week study of their smoking and able to provide consent.&lt;br&gt;&lt;br&gt;                Those who are eligible and consent to participate in the trial will be randomized at that point to intervention or comparator conditions. Randomization will be 1:1 at the individual level with no restriction (i.e. no blocking) and will be automated using a random number function.&lt;br&gt;&lt;br&gt;                After consenting, participants in the comparator condition will receive a message encouraging them to make a quit attempt within the next 4 weeks and reminding them of the importance of responding to follow-up requests which are designed to track their progress.&lt;br&gt;&lt;br&gt;                Participants in the intervention condition will receive the same advice as those in the comparator condition plus offer of the full version of the Smoke Free app free of charge, encouragement to use the app and a link to download it. The Smoke Free app is based on behaviour change techniques that would be expected from theory and evidence with face-to-face support to aid smoking cessation. It guides smokers through the first month of their quit attempt by helping them to maintain their resolve by setting a clear goal, monitoring their progress towards that goal and becoming aware of benefits of being smoke-free achieved to date. The app has several components:&lt;br&gt;                1. A calculator which tracks the total amount of money not spent on buying cigarettes and the number of cigarettes not smoked (‘Dashboard')&lt;br&gt;                2. A calendar which tracks the amount of time elapsed since cessation (‘Dashboard')&lt;br&gt;            
    </Intervention>
    <Primary_outcome>Self-reported smoking cessation for at least 26 weeks, assessed 30 weeks after enrolment
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Assessed using self report:&lt;br&gt;                1. Having made at least one quit attempt in the 4 weeks following enrolment in the study&lt;br&gt;                2. Smoking cessation for at least 12 weeks, assessed 4 weeks after enrolment&lt;br&gt;                3. Downloading or using the Smoke Free app at least once, assessed 30 weeks after enrolment&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;CEHP/2016/556
    </Secondary_ID>
    <Source_Support>Cancer Research UK
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 06/09/2019, UCL Research Ethics Committee (University College London, 2 Taviton St, London WC1E 6BT, UK. +44 (0)207 6798717; ethics@ucl.ac.uk), ref: CEHP/2016/556
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/12/2021
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>11654627
    </Internal_Number>
    <TrialID>CTRI/2020/09/027709
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Patterns of peritoneal cancer spread from various primary tumors
    </Public_title>
    <Scientific_title>Patterns of Peritoneal Dissemination and Response to Systemic Chemotherapy in Common and Rare Peritoneal Tumors Treated with Cytoreductive Surgery- A Prospective Multi-centric study - PRECINCT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Zydus hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200910
    </Date_registration3>
    <Date_registration>10-09-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46131
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>11-09-2020
    </Date_enrollement>
    <Target_size>1600
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia
    </Countries>
    <Contact_Firstname>Aditi BHATT
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Zydus Hospital Road, Thaltej 
    </Contact_Address>
    <Contact_Email>aditimodi31@gmail.com
    </Contact_Email>
    <Contact_Tel>09686447863
    </Contact_Tel>
    <Contact_Affiliation>Zydus hospital, surgical oncology, room no 5
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.	All patients undergoing cytoreductive surgery for peritoneal metastases from colorectal, ovarian, gastric and appendiceal primary tumors and peritoneal mesothelioma will be included.  &lt;br/ &gt;&lt;br&gt;2.	Only patients with biopsy proven PM will be included (pathological evaluation is not mandatory prior to CRS if imaging or exploration confirms the presence of disease).  &lt;br/ &gt;&lt;br&gt;3.	Patient undergoing debulking procedures will be included &lt;br/ &gt;&lt;br&gt;4.	For ovarian cancer, only patients with FIGO stage III-C or IV-A will be included. Patients undergoing surgery at first diagnosis, after NACT and those undergoing surgery for recurrent disease will be included. Patients without peritoneal disease will be excluded.  &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: â?¢	Patients undergoing second look procedures with no evidence of peritoneal metastases will be excluded.  &lt;br/ &gt;&lt;br&gt;â?¢	Patients undergoing palliative procedures that do not involve tumor debulking will be excluded unless the goal of surgery was to obtain a complete cytoreduction i.e. procedures performed with the intention of palliation alone like a diverting oâ??stomy will be excluded.  &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: K669- Disorder of peritoneum, unspecified

    </Condition>
    <Intervention/>
    <Primary_outcome>Disease distribution in the peritoneal cavityTimepoint: At 6 months, after completion of recruitment and at 1 year, 3 years and 5 years from the end of recruitment
    </Primary_outcome>
    <Secondary_outcome>Morphology of peritoneal metastasesTimepoint: At the time of surgery;Overall survivalTimepoint: At 1 year, 3 and 5 years after recruitment;Pathological response to systemic chemotherapyTimepoint: At the time of surgery;Pattern of lymph node involvementTimepoint: At the time of surgery;Progression-free survivalTimepoint: At 1, 3 and 5 years after recruitment
    </Secondary_outcome>
    <Secondary_ID>none
    </Secondary_ID>
    <Source_Support>Zydus hospitaal
    </Source_Support>
    <Ethics_review_status>Not Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;27/07/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Lyon-sud Ethics Committee;Zydus Hospital Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>9662840
    </Internal_Number>
    <TrialID>ISRCTN17717312
    </TrialID>
    <Last_Refreshed_on>17 August 2020
    </Last_Refreshed_on>
    <Public_title>CORONATION: Coronavirus (COVID-19) multinational observational registry
    </Public_title>
    <Scientific_title>Coronavirus (COVID-19) Multinational observational registry (CORONATION)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Cambridge University Hospitals NHS Foundation Trust
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200723
    </Date_registration3>
    <Date_registration>23/07/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN17717312
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>30/07/2020
    </Date_enrollement>
    <Target_size>10000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational epidemiological study (Screening)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Kerrie
    </Contact_Firstname>
    <Contact_Lastname>Brusby
    </Contact_Lastname>
    <Contact_Address>
                    Cambridge Clinical Trials Centre (CCTU)
                    Cambridge University Hospitals (CUH) NHS Foundation Trust
                    Addenbrooke’s Hospital
                    Cambridge Biomedical Campus
                    Box 4
    </Contact_Address>
    <Contact_Email>add-tr.coronation@nhs.net
    </Contact_Email>
    <Contact_Tel>+44 (0)1223254472
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                All COVID-19 cases are eligible for inclusion (COVID-19 cases that pre-decease the start of the registry are eligible)&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Does not meet inclusion criteria
    </Exclusion_Criteria>
    <Condition>COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)
    </Condition>
    <Intervention>&lt;br&gt;                The CORONATION registry is a patient-level disease registry capturing identifiable patient data on UK COVID-19 cases and anonymised or identifiable data on international COVID-19 cases.&lt;br&gt;&lt;br&gt;                Care teams will collect demographic and clinical data on confirmed COVID-19 cases and enter this information into a database. This will be undertaken through a simple enrollment process and linkage with other datasets.&lt;br&gt;&lt;br&gt;                Baseline data collected will include baseline demographic data, baseline clinical data (comorbidities, medication, COVID-19 status and symptoms).&lt;br&gt;
    </Intervention>
    <Primary_outcome>Demographic and clinical data on confirmed COVID-19 cases (comorbidities, medication, COVID-19 status and symptoms) collected regularly from participating centres by entering data into an online portal
    </Primary_outcome>
    <Secondary_outcome>There are no secondary outcome measures
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;CCTU0304, IRAS 282239
    </Secondary_ID>
    <Source_Support>Cambridge Biomedical Research Centre 
    </Source_Support>
    <Secondary_Sponsor>University of Cambridge
    </Secondary_Sponsor>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 20/07/2020, University of Cambridge Human Biology Research Ethics Committee (17 Mill Lane, Cambridge, CB2 1RX; +44 (0)1223 766894; cb480@admin.cam.ac.uk), ref: HBREC.2020.32
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>24/04/2025
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>11653590
    </Internal_Number>
    <TrialID>CTRI/2020/07/026672
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Mental health affected by COVID-19
    </Public_title>
    <Scientific_title>Mental health among individuals dealing with COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Tata Memorial Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200718
    </Date_registration3>
    <Date_registration>18-07-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45764
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>28-07-2020
    </Date_enrollement>
    <Target_size>2000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Arjun Singh
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Dr. E Borges Marg, Parel, Mumbai 400012, India Dr. E Borges Marg, Parel, Mumbai 400012, India
    </Contact_Address>
    <Contact_Email>arjun193@gmail.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Tata Memorial Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Confirmed cases of COVID-19 diagnosed using RT-PCR (real-time reverse transcription polymerase chain reaction) &lt;br/ &gt;&lt;br&gt;2. Healthcare workers and patient relatives dealing with COVID-19 patients  &lt;br/ &gt;&lt;br&gt;3. Age between 18-65 years &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Non consenting participants
    </Exclusion_Criteria>
    <Condition>Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

    </Condition>
    <Intervention/>
    <Primary_outcome>PHQ 9 and/or WHO-BREF scoreTimepoint: Cross sectional at the time of administration of questionnaire
    </Primary_outcome>
    <Secondary_outcome>NATimepoint: NA
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Not applicable
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/07/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Tata Memorial Hosptial
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>11653252
    </Internal_Number>
    <TrialID>CTRI/2020/07/026334
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>A study to find out the current management practices  of Sleep inducing methods, Pain reducing methods, and treatment used for management of serious disturbances in brain functions in patients admitted in intensive care units.
    </Public_title>
    <Scientific_title>Sedation, Analgesia and Delirium MANagement: an international audit of adult medical, surgical, trauma, and neuro-intensive care patients - SANDMAN Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Tata Memorial Centre
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200702
    </Date_registration3>
    <Date_registration>02-07-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44719
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>31-07-2020
    </Date_enrollement>
    <Target_size>2000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>DrSheila Nainan Myatra
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Department of Anesthesia, Critical Care and Pain, Main Building, Second Floor, Tata Memorial Hospital, Dr.E Borges Road, Parel 
    </Contact_Address>
    <Contact_Email>sheila150@hotmail.com
    </Contact_Email>
    <Contact_Tel>9820156070
    </Contact_Tel>
    <Contact_Affiliation>Tata Memorial Centre
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. All adults (â?¥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours will be included. &lt;br/ &gt;&lt;br&gt;2. We will include medical, surgical, and neurological patients.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: There are no exclusion criteria
    </Exclusion_Criteria>
    <Condition>Health Condition 1: R098- Other specified symptoms and signsinvolving the circulatory and respiratory systems

    </Condition>
    <Intervention>Intervention1: NIL: NIL&lt;br&gt;Control Intervention1: NIL: NIL&lt;br&gt;
    </Intervention>
    <Primary_outcome>To capture an overview of sedation, analgesia and delirium management strategies used in intensive care units around the world.Timepoint: 3 months after enrollment
    </Primary_outcome>
    <Secondary_outcome>To describe and compare management between specific ICU patient groups:1 Medical patients (specifically sepsis and acute respiratory distress syndrome (ARDS)) &lt;br/ &gt;&lt;br&gt;2 Surgical patients &lt;br/ &gt;&lt;br&gt;3Trauma and Burns patients &lt;br/ &gt;&lt;br&gt;4 Neurocritical care patients &lt;br/ &gt;&lt;br&gt;5 Cardiogenic shock patients &lt;br/ &gt;&lt;br&gt;6 Patients receiving palliative careTimepoint: 3 months after enrollment;To describe international practice in ICU, and practice variation in the use of drugs, and monitoring for PAD;Timepoint: 3 months after enrollment;To quantify the adherence to the PAD clinical guidelinesTimepoint: 3 months after enrollment
    </Secondary_outcome>
    <Secondary_ID>Project No_900629 Version 3.1_20July2019
    </Secondary_ID>
    <Source_Support>Tata Memorial Hospital, Dr.E Borges Road, Parel Mumbai Maharashtra India 400012
    </Source_Support>
    <Secondary_Sponsor>Not Any
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>29/06/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>12057010
    </Internal_Number>
    <TrialID>ISRCTN80453162
    </TrialID>
    <Last_Refreshed_on>21 March 2022
    </Last_Refreshed_on>
    <Public_title>The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery (COVER study)
    </Public_title>
    <Scientific_title>The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery. An international cohort study (COVER)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>University Hospitals Coventry and Warwickshire NHS Trust
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200414
    </Date_registration3>
    <Date_registration>14/04/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN80453162
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>09/04/2020
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational longitudinal study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Ruth;Sandip
    </Contact_Firstname>
    <Contact_Lastname>Benson;Nandhra
    </Contact_Lastname>
    <Contact_Address>Vascular and Endovascular Research Network (President);Vascular and Endovascular Research Network
    </Contact_Address>
    <Contact_Email>vern.arterial.disease@gmail.com;vern.arterial.disease@gmail.com
    </Contact_Email>
    <Contact_Tel>+44 (0)121 4143344;+44 (0)191 2336161
    </Contact_Tel>
    <Contact_Affiliation>;
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Any patient with a vascular condition
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Does not meet inclusion criteria
    </Exclusion_Criteria>
    <Condition>Any vascular condition, including: aortic or other type of aneurysmal disease, peripheral arterial disease, venous disease, vascular malformations, trauma, major haemorrhage, access (for renal dialysis), carotid (and cerebrovascular) disease, any other type of pathology treated by vascular surgeons. &lt;br&gt;Circulatory System
    </Condition>
    <Intervention>&lt;br&gt;                This project is a three-tiered study designed to fully elucidate the impact of the COVID-19 pandemic on vascular surgery across the world.&lt;br&gt;&lt;br&gt;                The aim of Tier 1 is to document how the provision and availability of vascular services evolves over time per unit/region/country.&lt;br&gt;&lt;br&gt;                The aim of Tier 2  is to prospectively capture data on all vascular procedures performed during the pandemic and understand the impact on outcomes in the short and medium-term (up to 1 year).&lt;br&gt;&lt;br&gt;                The aim of Tier 3 is to document (prospectively) deviations from standards of care/practice during the pandemic in vascular patients.&lt;br&gt;&lt;br&gt;                The main objective of the COVER study is to understand and evaluate the impact of the COVID-19 pandemic on global vascular practice and the effect on outcomes for patients presenting/receiving treatment during the pandemic.&lt;br&gt;                Population (patients) – All patients with a vascular pathology.&lt;br&gt;                Outcome of interest – Tier 1: state of vascular services per centre weekly; Tier 2: procedures performed in each centre; Tier 3: assessment of longer-term outcomes.&lt;br&gt;                Time – end of study 12 months after the end of the COVID19 pandemic.&lt;br&gt;&lt;br&gt;                The study is formally supported by the Vascular Society of Great Britain and Ireland (VSGBI),  the British Society for Endovascular Therapy (BSET), the Rouleaux Club, the NIHR, SingVasc and several national vascular surgery societies in Europe, Asia, Australia, New Zealand, and the Americas.&lt;br&gt;
    </Intervention>
    <Primary_outcome>&lt;br&gt;                1. Structure and processes within the vascular service measured using a novel online questionnaire weekly until the end of data collection&lt;br&gt;                2. Document all vascular surgery and interventional procedures performed using an online purpose-built data collection tool (per centre/patient) at baseline, time/date of surgery, date of discharge from hospital, three, six, and twelve months:&lt;br&gt;                2.1. Type of procedure performed&lt;br&gt;                2.2. Time taken from presentation to the surgical team to intervention&lt;br&gt;                2.3. Mode of referral (primary vs. secondary care)&lt;br&gt;                2.4. Site of surgery – hub or spoke hospital&lt;br&gt;                2.5. Imaging modalities used and timings&lt;br&gt;                2.6. Emergency classification i.e. urgent/emergency/elective&lt;br&gt;                2.7. Operative technique(s) and device(s) used&lt;br&gt;                2.8. Mode(s) of anaesthesia (local, regional, general, locoregional, other)&lt;br&gt;                2.9. Whether suspected or confirmed COVID-19 positive (+ve) at time of surgery, COVID-19 +ve after surgery, or COVID-19 negative (-ve)&lt;br&gt;                2.10. Documentation of changes to usual practice for this specific procedure as per surgeon’s standard protocol (type of procedure, type of anaesthetic, post-procedural destination)&lt;br&gt;                3. Management of all referred urgent vascular cases using the online survey, focusing on:&lt;br&gt;                3.1.  Chronic Limb Threatening Ischaemia (CLTI):&lt;br&gt;                3.1.1. Decision to discharge/admit/refer to a "hot"/emergency clinic&lt;br&gt;                3.1.2. Decision for endovascular or open surgery first&lt;br&gt;                3.1.3. Decision for best medical therapy or palliation or primary amputation&lt;br&gt;                3.2. Carotid disease:&lt;br&gt;                3.2.1. Number of patients managed with best medical therapy (BMT)&lt;br&gt;                3.2.2. Modifications to the indication and decision for carotid endarterectomy (CEA)&lt;br&gt;                3.2.3. Delays to treatment due to lack of theatre/bed availability&lt;br&gt;                3.3. Abdominal Aortic Aneurysm (AAA)&lt;br&gt;                3.3.1. Increasing use of Endovascular repair (if applicable)&lt;br&gt;                3.3.2. Changes to criteria for intervention&lt;br&gt;                3.3.3. Decisions for palliation, i.e. ‘turn down’&lt;br&gt;                3.4. Acute Aortic syndrome (AAS)&lt;br&gt;                3.4.1. Decision to manage in non-critical care beds&lt;br&gt;                3.4.2. Changes to imaging protocol at unit level&lt;br&gt;                3.4.3. Decision to defer surgery&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Collected after surgery has been performed at three, six, and twelve months using patient records:&lt;br&gt;                1.1. Re-admission&lt;br&gt;                1.2. Re-intervention&lt;br&gt;                1.3. All-cause mortality&lt;br&gt;                1.4. Operation-specific morbidity&lt;br&gt;                1.5. Morbidity&lt;br&gt;                1.6. [If COVID-19 +ve] - respiratory outcome, admission to intensive care unit&lt;br&gt;                2. Condition-specific outcomes at 3, 6 months and 1 year:&lt;br&gt;                2.1. CLTI - limb salvage, amputation free survival, all-cause mortality&lt;br&gt;                2.2. Carotid disease - ipsilateral stroke rate, any stroke rate, all-cause mortality&lt;br&gt;                2.3. AAA - aneurysm-related mortality, all-cause mortality&lt;br&gt;                2.4. AAS - complication rate including ruptures, all-cause mortality&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;COVER_01, IRAS 282224
    </Secondary_ID>
    <Source_Support>National Institute for Health Research
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 02/04/2020, Liverpool Central NHS Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8056; liverpoolcentral.rec@hra.nhs.uk), ref: 20/NW/0196
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/04/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>11650500
    </Internal_Number>
    <TrialID>CTRI/2020/02/023582
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>An international,observational study to collect information about the practices of blood transfusion followed by doctors working in intensive care units.
    </Public_title>
    <Scientific_title>International Point Prevalence Study of Intensive Care Unit Transfusion Practices (InPUT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Academic Medical Center
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200225
    </Date_registration3>
    <Date_registration>25-02-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=40701
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>28-02-2020
    </Date_enrollement>
    <Target_size>10000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Dr Sheila Nainan Myatra
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Room No 5, Department of Anesthesia, Critical care and Pain, Main building, Dr E Borges Road, parel 
    </Contact_Address>
    <Contact_Email>sheila150@hotmail.com
    </Contact_Email>
    <Contact_Tel>9820156070
    </Contact_Tel>
    <Contact_Affiliation>Tata Memorial Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. All adult (age more than 18yrs)patients admitted to the ICU in a pre-specified week
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients younger than 18 years old.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: R69- Illness, unspecified

    </Condition>
    <Intervention>Intervention1: Nil: Nil&lt;br&gt;Control Intervention1: Nil: Nil&lt;br&gt;
    </Intervention>
    <Primary_outcome>1.To describe current transfusion practiceTimepoint: once a day after intensive care unit admission till discharge or maximum upto 28 days
    </Primary_outcome>
    <Secondary_outcome>Differences of transfusion practices between different patient subgroupsTimepoint: Once at the time of data analysis;Differences of transfusion regimes between world regionsTimepoint: Once at the time of data analysis;Mortality and length of stay in the intensive care unitTimepoint: Once a day after intensive care unit admission till discharge or maximum upto 28 days
    </Secondary_outcome>
    <Secondary_ID>Project No 3397 Version 5.0 dated 17 Oct 2019
    </Secondary_ID>
    <Source_Support>Tata Memorial Hospital, Dr.E Borges Road, Parel Mumbai 400012
    </Source_Support>
    <Secondary_Sponsor>Not Any
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>23/01/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>11649335
    </Internal_Number>
    <TrialID>CTRI/2019/12/022417
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Alternative Approach for General Health Issues
    </Public_title>
    <Scientific_title>Frequency Embedded Crystal Ball Water Technology - FECB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Portoworld
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191218
    </Date_registration3>
    <Date_registration>18-12-2019
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=38957
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>20-12-2019
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized Factorial Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Case Record Numbers  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Angola;Argentina;Australia;Bahamas;Bangladesh;Belarus;Belgium;Benin;Bhutan;Botswana;Brazil;Bulgaria;Burundi;Cambodia;Canada;Central African Republic;Chad;China;Colombia;Congo;Croatia;Cuba;Democratic People's Republic of Korea;Ecuador;Egypt;El Salvador;Equatorial Guinea;Ethiopia;France;Gambia;Germany;Greece;Guinea;Guyana;Haiti;Hong Kong;India;Indonesia;Iran (Islamic Republic of);Ireland;Israel;Japan;Kazakhstan;Kuwait;Liberia;Libyan Arab Jamahiriya;Malaysia;Marshall Islands;Mauritius;Mexico;Morocco;Myanmar;Namibia;Nauru;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Saudi Arabia;Serbia ;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Sweden;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>O Mohammed Shadab
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Room No - H 6A , Department of public information and Records  , Portoworld, krupa colony,
First Avenue , Ashok Nagar,Chennai 
    </Contact_Address>
    <Contact_Email>portoworld1@gmail.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Portoworld
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Healthy Induvidual Above the age of 18yrs and Below 70yrs are involved
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Any Induvidual below the age of Five Years and pregnant ladies are exempted from this trial
    </Exclusion_Criteria>
    <Condition/>
    <Intervention>Intervention1: FREQUENCY EMBEEDED WATER: DIFFERENT FREQUENCIES ARE EMBEEDED IN A CRYSTAL BALL AND THEN THE BALL WITH FREQUENCY IS DIPPED IN A DRINKING WATER FOR 10 MINUTES AND THE WATER IS PRESENTED TO PATIENTS&lt;br&gt;Control Intervention1: NOT APPLICABLE: NOT APPLICABLE&lt;br&gt;
    </Intervention>
    <Primary_outcome>General Health AND IMMUNITYTimepoint: 30 days
    </Primary_outcome>
    <Secondary_outcome>Blood sugar becomes NormalTimepoint: 30 days;Metabolism impovedTimepoint: 20 days;Noctonal Pain in joints were reducedTimepoint: 3 months;Testosterone Level increasedTimepoint: 30 days
    </Secondary_outcome>
    <Secondary_ID>IYRF/IND/TN/8947
    </Secondary_ID>
    <Source_Support>Portoworld
H-6A , krupa colony,
First Avenue , Ashok Nagar,Chennai
    </Source_Support>
    <Secondary_Sponsor>Dr Krishnamurthy Kannan
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>20/07/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>International Youth Research Foundation
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>12601533
    </Internal_Number>
    <TrialID>PACTR202001829834757
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Physical activity effectiveness for chronic non-specific low back pain treatment in Burundi
    </Public_title>
    <Scientific_title>Physical activity in chronic low back pain: A randomized controlled clinical trial comparing group-based walking plus yoga versus individual physical therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor/>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191203
    </Date_registration3>
    <Date_registration>03/12/2019
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=9580
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>03/02/2020
    </Date_enrollement>
    <Target_size>56
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Sealed opaque envelopes
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Burundi
    </Countries>
    <Contact_Firstname>Oyene
    </Contact_Firstname>
    <Contact_Lastname>Kossi
    </Contact_Lastname>
    <Contact_Address>Parcelle I, lot W64
    </Contact_Address>
    <Contact_Email>oyene.kossi@gmail.com
    </Contact_Email>
    <Contact_Tel>+22995016605
    </Contact_Tel>
    <Contact_Affiliation>Professor and Researcher at National School of Public Health and Epidemiology of Parakou University in Benin
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - 18-65 years old&#x0D;&lt;br&gt;- Patients willing to attend a 12-wk treatment programme&#x0D;&lt;br&gt;- Patients with chronic (=3 mo) or recurrent (=3 episodes in previous 12 mo) LBP of mechanical origin &#x0D;&lt;br&gt;- Sufficiently mobile: eg, can get up off floor unaided
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Cognitive deficit&#x0D;&lt;br&gt; - Pregnant women&#x0D;&lt;br&gt;- Red flags indicating serious spinal pathology (eg, cancer, cauda equina lesion)&#x0D;&lt;br&gt;- Radicular pain indicative of nerve root compression&#x0D;&lt;br&gt;- Patients diagnosed with severe spinal stenosis, spondylolisthesis, and fibromyalgia&#x0D;&lt;br&gt;- Comorbidities that prevent the patient from participating in group-based physical activity&#x0D;&lt;br&gt;- Contraindication to physical activity
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Musculoskeletal Diseases;Musculoskeletal Diseases
    </Condition>
    <Intervention>;group based of yoga plus graded walking;individual physical therapy 
    </Intervention>
    <Primary_outcome>Activity limitations (Roland-Morris Disability questionnaire)
    </Primary_outcome>
    <Secondary_outcome>Pain intensity (Numerical rating scale);Muscular endurance (Shirado test, Sorensen test);Depression (Beck Depression Inventory);Patient beliefs (Fear-Avoidance Beliefs Questionnaire);Physical Fitness (Borg Rating of Perceived Exertion scale, resting heart rate);Self-perception of performance (Canadian occupational performance measure);Participation (5-Item Pain Disability Index)
    </Secondary_outcome>
    <Source_Support>Wallonie Bruxelles International and Catholic University of Louvain
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>12/12/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>insp@insp.bi
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>National ethics committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+25722269720
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>insp@insp.bi
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>12601527
    </Internal_Number>
    <TrialID>PACTR202001714888482
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Multimodal physical activity for chronic stroke survivors
    </Public_title>
    <Scientific_title>Combined and collective physical activity for chronic stroke survivors; the CBCS: Protocol for a randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>UCLouvain Scholarships
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191202
    </Date_registration3>
    <Date_registration>02/12/2019
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=9571
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>03/02/2020
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Crossover: all participants receive all interventions in different sequence during study,Randomised,Simple randomization using a randomization table created by a computer software program,Sealed opaque envelopes
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Burundi
    </Countries>
    <Contact_Firstname>Ildephonse;Alexis
    </Contact_Firstname>
    <Contact_Lastname>Nduwimana;SINZAKARAYE
    </Contact_Lastname>
    <Contact_Address>kinanira 3;Boulevard du 28 Novembre
    </Contact_Address>
    <Contact_Email>ilwimana@gmail.com;sinzalex@yahoo.fr
    </Contact_Email>
    <Contact_Tel>+25779376031;+25779184008
    </Contact_Tel>
    <Contact_Affiliation>physiotherapist and PhD student at Catholic University of Louvain;Professor at Faculty of medecine National University of Burundi
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: •	Chronic stage of stroke (minimum 6 months after the first stroke)&#x0D;&lt;br&gt;•	Adults (18-75 years old)&#x0D;&lt;br&gt;•	Absence of cognitive impairment and dementia: CSI-D=7&#x0D;&lt;br&gt;•	Non-depressed patients: HADS=7&#x0D;&lt;br&gt;•	Less disabled patient: MRS=3&#x0D;&lt;br&gt;•	Not associated to other interventions related to walking and / or any form of physical activity&#x0D;&lt;br&gt;•	Sufficient mobility: able to walk 10 m alone or with a technical assistance&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: •	Diseases or Comorbidities that prevent the patient from participating in group-based physical activity&#x0D;&lt;br&gt;•	Contraindication to physical activity&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Nervous System Diseases;Nervous System Diseases
    </Condition>
    <Intervention>;CBCS;Sociocultural group
    </Intervention>
    <Primary_outcome>Activity limitation: ACTIVLIM stroke scale 
    </Primary_outcome>
    <Secondary_outcome>Impairments: &#x0D;&lt;br&gt;•	Balance: BBS (Berg Balance Scale) and TUG (Timed-Up and Go Test)&#x0D;&lt;br&gt;•	Global impairments: SIAS (Stroke impairments assessment Set)&#x0D;&lt;br&gt;;Functional autonomy: &#x0D;&lt;br&gt;•	Manual dexterity: BBT (Box and block test)&#x0D;&lt;br&gt;•	Manual ability: ABILHAND scale for stroke&#x0D;&lt;br&gt;•	Walking speed: 10mWT (10 meter Walk test)&#x0D;&lt;br&gt;•	Walking performances: 6MWT (6 minute Walk test)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;;Participation : PM-scale (Participation Measurement scale);Quality of life: SS-QOL (Stroke specific Quality of Life scale)
    </Secondary_outcome>
    <Source_Support>Wallonie Bruxelles International scholarship;International Action Committee  Universite Catholique de Louvain
    </Source_Support>
    <Secondary_Sponsor>Wallonie Bruxelles International WBI scholarships
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>02/01/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>nyandwijo@yahoo.fr
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>National Ethics Committee for the Protection of Human Beings Subject to Biomedical and Behavioral Research
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+25722217565
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>nyandwijo@yahoo.fr
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>11574584
    </Internal_Number>
    <TrialID>NCT04061954
    </TrialID>
    <Last_Refreshed_on>8 November 2021
    </Last_Refreshed_on>
    <Public_title>Umuryango Ukomera Uri Hamwe - Families Are Strong Together
    </Public_title>
    <Scientific_title>Improving Family Cohesion Using a Comprehensive Family Program Addressing Parental Skills and Mental Health Issues in Traumatised Parents in Burundi
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190817
    </Date_registration3>
    <Date_registration>17/08/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04061954
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 6, 2019
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burundi
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents who reported in a preliminary assessment to experience/or having experienced&#x0D;&lt;br&gt;             at least 3 of the following 5 conditions: (1) marital conflicts (2) difficulties to&#x0D;&lt;br&gt;             sleep in the past 4 weeks (3) Nightmares in the past 4 weeks (4) current social&#x0D;&lt;br&gt;             withdrawal (5) lost a loved one during the past year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents who spend time at the landfill&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents with children between 7 and 16 who spend time at the landfill&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Posttraumatic Stress Disorder;Aggressive Behaviour;Parental Maltreatment;Days Spent at the Landfill
    </Condition>
    <Intervention>Behavioral: Comprehensive family intervention including individual sessions of FORNET
    </Intervention>
    <Primary_outcome>In parents: Change of load of traumatic symptoms measured via the PTSD Symptom Scale Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5);In parents: Change of number of aggressive acts measured via an adaption of the Domestic and Community Violence;In children: Change in experienced parental rejection measured via the short version of the Parental Acceptance Rejection Questionnaire;In children: Change of experienced parental maltreatment measured via a shortened version of the Maltreatment and Abuse Chronology of Exposure (MACE);In children: Change of number of days spent at the landfill
    </Primary_outcome>
    <Secondary_ID>UKCR19
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Vivo international e.V.;Psychologues sans Frontières Burundi;Université Lumière de Bujumbura
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>10323138
    </Internal_Number>
    <TrialID>NCT03846154
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Reintegrating Children Living at Landfills in Burundi Into Society by Means of a Comprehensive Family Program Addressing Maltreatment and Mental Health Symptoms
    </Public_title>
    <Scientific_title>Reintegrating Children Living at Landfills in Burundi Into Society by Means of a Comprehensive Family Program Addressing Maltreatment and Trauma-related Mental Health Symptoms
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190215
    </Date_registration3>
    <Date_registration>15/02/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03846154
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 1, 2018
    </Date_enrollement>
    <Target_size>96
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burundi
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Spending days at the landfills of Bujumbura&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Posttraumatic Stress Disorder;Aggressive Behaviour;Parental Maltreatment;Days Spent at the Landfill
    </Condition>
    <Intervention>Behavioral: Comprehensive family intervention including individual sessions of FORNET
    </Intervention>
    <Primary_outcome>Change of load of traumatic symptoms measured via the University of California at Los Angeles Posttraumatic Stress Disorder Reaction Index (scale administered by Clinicians);Change of number of aggressive acts measured via an adaption of the Domestic and Community Violence Checklist;Change of experienced parental maltreatment measured via a shortened version of the Maltreatment and Abuse Chronology of Exposure (MACE);Change of number of days spent at the landfill
    </Primary_outcome>
    <Secondary_ID>UKCR18
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Vivo international e.V.;Psychologues sans Frontières Burundi;Université Lumière de Bujumbura
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>8116835
    </Internal_Number>
    <TrialID>ISRCTN14071325
    </TrialID>
    <Last_Refreshed_on>17 June 2019
    </Last_Refreshed_on>
    <Public_title>An international study to investigate rates of death and illness following liver surgery
    </Public_title>
    <Scientific_title>International Snapshot Study on the Outcomes of Liver surgery - LiverGroup.org                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Royal Free London NHS Foundation Trust, UCL Partners
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190213
    </Date_registration3>
    <Date_registration>13/02/2019
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN14071325
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2019
    </Date_enrollement>
    <Target_size>2000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational snapshot study  (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. All liver surgery indications (including benign and living donor resections, open, laparoscopic or robotic surgery, single wedge resections to extended liver resections, single- or two-stage hepatectomies, procedures with liver volume enhancement such as PVE, PVL, ALPPS, resections involving cold perfusion (ex-situ and ante-situ)&lt;br&gt;                2. Any co-morbidity&lt;br&gt;&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Liver transplantation&lt;br&gt;                2. Imaging-guided RFA, MWA, or other ablation techniques&lt;br&gt;                3. Liver biopsies&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Any indication for liver surgery &lt;br&gt;Surgery
    </Condition>
    <Intervention>The intervention includes any type of liver surgery. The patients's progress will be observed from the day of the operation until hospital discharge as well as up to 90 days postoperatively.
    </Intervention>
    <Primary_outcome>Death recorded up to 90 days postoperatively using the patients' medical records
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Postoperative complications as measured by the Clavien-Dindo Classification, FABIB Liver-Specific Classification and the Comprehensive Complication Index® (CCI®)&lt;br&gt;                2. Liver failure as measured by the FABIB Liver-Specific Classification, the ISGLS criteria and the 50-50 criteria up to 90 days postoperatively&lt;br&gt;                3. Length of hospital stay (defined as the duration of hospitalization from the day of the operation until the day of discharge from the hospital) recorded up to 90 days postoperatively using the patients' medical records&lt;br&gt;                4. Rehospitalization (defined as any readmission to any hospital within 90 days from the operation) assessed using the patients' medical records up to 90 days postoperatively using the patients' medical records&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>NCT03768141;v.1.3
    </Secondary_ID>
    <Source_Support>Royal Free Hospital, Universidad de Zaragoza
    </Source_Support>
    <Secondary_Sponsor>Department of Surgery, University Hospital Miguel Servet, University of Zaragoza, Spain
    </Secondary_Sponsor>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>This project is considered as an audit and does not require ethics committee approval in the UK. 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>10/03/2020
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>12601088
    </Internal_Number>
    <TrialID>PACTR201905610589889
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Safety and efficacy of artesunate-amodiaquine for the treatment of uncomplicated malaria in Burundi&#x0D;

    </Public_title>
    <Scientific_title>Safety and efficacy of artesunate-amodiaquine in four sentinel sites in Burundi for the treatment of uncomplicated malaria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Ministere de la Sante Publique
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181205
    </Date_registration3>
    <Date_registration>05/12/2018
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=5771
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>0 Month(s)
    </Inclusion_agemin>
    <Inclusion_agemax>23 Month(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>15/04/2019
    </Date_enrollement>
    <Target_size>352
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Crossover: all participants receive all interventions in different sequence during study,Non-randomised,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-4
    </Phase>
    <Countries>Burundi;Burundi;Burundi;Burundi
    </Countries>
    <Contact_Firstname>Baza
    </Contact_Firstname>
    <Contact_Lastname>Bismas
    </Contact_Lastname>
    <Contact_Address>Boulevard du 28 Novembre
    </Contact_Address>
    <Contact_Email>bazad@who.int
    </Contact_Email>
    <Contact_Tel>+25779663880
    </Contact_Tel>
    <Contact_Affiliation>Medical officer
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Age between 6 and 120 months (6 months and 10 years).&#x0D;&lt;br&gt;Mono-infection with P. falciparum confirmed by positive blood smear (i.e. no mixed infection).&#x0D;&lt;br&gt;Parasitemia of 1000 - 200.000 parasites/µl.&#x0D;&lt;br&gt;Presence of axillary temperature = 37.5 °C or history of fever during the past 24 h&#x0D;&lt;br&gt;Ability to swallow oral medication.&#x0D;&lt;br&gt;Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule.&#x0D;&lt;br&gt;Informed consent from the patient or from a parent or guardian in the case of children aged less than age of majority.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Pesence of general danger signs in children aged under 12 years or signs of severe falciparum malaria according to the definitions of WHO.&#x0D;&lt;br&gt;Mixed or mono-infection with another Plasmodium species detected by microscopy.&#x0D;&lt;br&gt;Presence of severe malnutrition defined as a child aged between 6-60 months whose weight-for-high is below –3 z-score, or has symmetrical oedema involving at least the feet or has a mid-upper arm circumference &lt; 115 mm).&#x0D;&lt;br&gt;Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS).&#x0D;&lt;br&gt;Regular medication, which may interfere with antimalarial pharmacokinetics.&#x0D;&lt;br&gt;History of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s).
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;Evaluation de l efficacite et de l innocute des antipaludiques ;There is no control group in a phse IV
    </Intervention>
    <Primary_outcome>Early treatment failure&lt;br&gt;•	danger signs or severe malaria on day 1, 2 or 3 in the presence of parasitaemia;&lt;br&gt;•	parasitaemia on day 2 higher than on day 0, irrespective of axillary temperature;&lt;br&gt;•	parasitaemia on day 3 with axillary temperature = 37.5 ºC;&lt;br&gt;•	parasitaemia on day 3 = 25% of count on day 0.&lt;br&gt;Late treatment failure&lt;br&gt;Late clinical failure&lt;br&gt;•	danger signs or severe malaria in the presence of parasitaemia on any day between day 4 and day 28 in patients who did not previously meet any of the criteria of early treatment failure;&lt;br&gt;•	presence of parasitaemia on any day between day 4 and day 28 with axillary temperature &lt;br&gt;= 37.5 ºC or history of fever in patients who did not previously meet any of the criteria of early treatment failure.&lt;br&gt;Late parasitological failure&lt;br&gt;•	presence of parasitaemia on any day between day 7 and day 28 with axillary temperature &lt;br&gt;&lt; 37.5 ºC in patients who did not previously meet any of the criteria of early treatment failure or late clinical failure.&lt;br&gt;Adequate clinical and parasitological response&lt;br&gt;•	absence of parasitaemia on day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure.&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>To determine the polymorphism of molecular markers for antimalarial drug(s) resistance; K13, pfmdr1, dhfr et dhps.
    </Secondary_outcome>
    <Source_Support>WHO
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>19/10/2018;21/11/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>jpsindayirwanya@yahoo.fr;recsec@who.int
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comite National d Ethique ;WHO Ethical Research Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>25779921173;+41227911479
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>jpsindayirwanya@yahoo.fr;recsec@who.int
    </Ethics_review_contact_email>
    <results_url_link>https://www.who.int/malaria/areas/drug_resistance/en/
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>11642751
    </Internal_Number>
    <TrialID>CTRI/2018/09/015833
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>International, multi-centre study on comparing management and outcomes of children born with congenital diseases between Low-Â­, Middle-Â­ and Highâ??Income Countries.
    </Public_title>
    <Scientific_title>Management and Outcomes of Congenital Anomalies in Low-Â­, Middle-Â­ and Highâ??Income Countries:
A Multi-centre, International, Prospective Cohort Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Naomi Wright
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180926
    </Date_registration3>
    <Date_registration>26-09-2018
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=28425
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-10-2018
    </Date_enrollement>
    <Target_size>27201
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Algeria;Angola;Argentina;Australia;Bangladesh;Belgium;Bolivia;Bosnia and Herzegovina;Brazil;Brunei Darussalam;Burundi;Cambodia;Cameroon;Canada;Chile;China;Colombia;Democratic Republic of the Congo;Ecuador;Egypt;Ethiopia;France;Germany;Ghana;Guatemala;India;Indonesia;Iraq;Jordan;Kenya;Lao People's Democratic Republic;Libyan Arab Jamahiriya;Lithuania;Madagascar;Malawi;Malaysia;Mauritania;Mexico;Morocco;Myanmar;Nepal;New Zealand;Nigeria;Other;Pakistan;Peru;Philippines;Poland;Republic of Korea;Rwanda;Saudi Arabia;Singapore;South Africa;Spain;Sudan;Sweden;Switzerland;Tanzania;Thailand;Tunisia;Turkey;Uganda;United Kingdom;United States of America;Uzbekistan;Venezuela (Bolivarian Republic of);Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Dr Sundeep PT
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Associate Professor, Department of Pediatric Surgery, Kasturba Medical College, Manipal Academy of Higher Education, Manipal 
    </Contact_Address>
    <Contact_Email>vijay.kumar@manipal.edu
    </Contact_Email>
    <Contact_Tel>9845857787
    </Contact_Tel>
    <Contact_Affiliation>Kasturba Medical College, Manipal
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Any neonate, infant or child under the age of 16â??years, presenting for the first time, with one of the study conditions listed below can be included in the study. &lt;br/ &gt;&lt;br&gt;1. Oesophageal atresia with or without tracheoâ??oesophageal atresia &lt;br/ &gt;&lt;br&gt;2. Congenital diaphragmatic hernia &lt;br/ &gt;&lt;br&gt;3. Intestinal atresia &lt;br/ &gt;&lt;br&gt;4. Gastroschisis &lt;br/ &gt;&lt;br&gt;5. Exomphalos (also known as omphalocele) &lt;br/ &gt;&lt;br&gt;6. Anorectal Malformation &lt;br/ &gt;&lt;br&gt;7. Hirschsprungâ??s Disease
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Any child above the age of 16-years. &lt;br/ &gt;&lt;br&gt;2. Any neonate, infant or child with one of the study conditions who has previously received surgery for their condition.  &lt;br/ &gt;&lt;br&gt;3. If they have recently received surgery for their condition, were discharged and then represented with a complication of the surgery during the study period
    </Exclusion_Criteria>
    <Condition>Health Condition 1: Q391- Atresia of esophagus with tracheo-esophageal fistula
Health Condition 2: Q390- Atresia of esophagus without fistula
Health Condition 3: Q422- Congenital absence, atresia and stenosis of anus with fistula
Health Condition 4: Q423- Congenital absence, atresia and stenosis of anus without fistula
Health Condition 5: Q410- Congenital absence, atresia and stenosis of duodenum
Health Condition 6: Q412- Congenital absence, atresia and stenosis of ileum
Health Condition 7: Q411- Congenital absence, atresia and stenosis of jejunum
Health Condition 8: Q428- Congenital absence, atresia and stenosis of other parts of large intestine
Health Condition 9: Q420- Congenital absence, atresia and stenosis of rectum with fistula
Health Condition 10: Q421- Congenital absence, atresia and stenosis of rectum without fistula
Health Condition 11: Q790- Congenital diaphragmatic hernia
Health Condition 12: Q439- Congenital malformation of intestine, unspecified
Health Condition 13: Q792- Exomphalos
Health Condition 14: Q793- Gastroschisis

    </Condition>
    <Intervention>Intervention1: Not Applicable: Not Applicable&lt;br&gt;Control Intervention1: Not Applicable: Not Applicable&lt;br&gt;
    </Intervention>
    <Primary_outcome>All-cause, in-hospital mortality.Timepoint: 30 days following primary intervention or primary admission
    </Primary_outcome>
    <Secondary_outcome>Complications occurring within 30-Â­days of primary intervention including: &lt;br/ &gt;&lt;br&gt;1. Surgical site-Â­infection &lt;br/ &gt;&lt;br&gt;2. Wound dehiscence &lt;br/ &gt;&lt;br&gt;3. Need for re-Â­intervention &lt;br/ &gt;&lt;br&gt;4. Condition specific complications &lt;br/ &gt;&lt;br&gt;5. Condition specific outcome variables &lt;br/ &gt;&lt;br&gt;6. Length of hospital stay (time from admission to death in patients who do not survive) &lt;br/ &gt;&lt;br&gt;7. 30-Â­day post primary intervention mortalityTimepoint: 30 days
    </Secondary_outcome>
    <Secondary_ID>NCT03666767
    </Secondary_ID>
    <Source_Support>Kingâ??s Centre for Global Health and Health Partnerships, Kingâ??s College London, UK;Wellcome Trust
    </Source_Support>
    <Secondary_Sponsor>Ankit Raj Dr Vijay Kumar Dr Sundeep PT
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/08/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>11641611
    </Internal_Number>
    <TrialID>CTRI/2018/07/014693
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>A registry based study on treatment and survival of Retinoblatoma diagnosed children patients from different parts of the world
    </Public_title>
    <Scientific_title>Global Retinoblastoma Presentation 2017. - GRP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>NA
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180702
    </Date_registration3>
    <Date_registration>02-07-2018
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26126
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>02-07-2018
    </Date_enrollement>
    <Target_size>450
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Zimbabwe;Argentina;Armenia;Australia;Bangladesh;Benin;Brazil;Burundi;Canada;Chile;China;Cote d'Ivoire;Czech Republic;Democratic Republic of the Congo;Denmark;Ecuador;Egypt;Estonia;Ethiopia;Finland;France;Germany;Haiti;Honduras;Hungary;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Italy;Jamaica;Japan;Jordan;Kenya;Kyrgyzstan;Latvia;Lebanon;Lithuania;Malawi;Malaysia;Mali;Mexico;Morocco;Myanmar;Nepal;Netherlands;Nigeria;Pakistan;Panama;Paraguay;Peru;Philippines;Poland;Portugal;Republic of Korea;Russian Federation;Saudi Arabia;Singapore;Slovenia;South Africa;Spain;Sri Lanka;Sudan;Swaziland;Sweden;Switzerland;Thailand;Turkey;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uzbekistan;Viet Nam;Yemen;Zambia
    </Countries>
    <Contact_Firstname>Tushar Vora
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Tata Memorial Hospital,Department of Medical Oncology,Main building ground foor,OPD no.80, room no.14,Dr.E.borges Road,Parel, Mumbai.400012 
    </Contact_Address>
    <Contact_Email>tusharsvora@yahoo.com
    </Contact_Email>
    <Contact_Tel>9920428153
    </Contact_Tel>
    <Contact_Affiliation>Tata Memorial Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Participating center: in which treatment-naÃ¯ve Rb patients are seen and treated by any means. There is no lower or upper limit to the number of Rb patients seen in a center in order for it to become a participating center in the study. We are aiming to reach out and include as many Rb centers from around the world.  &lt;br/ &gt;&lt;br&gt;Subjects: All Rb patients that presented to a participating center from 01/01/2017-31/12/2017 and were offered/received treatment of any type (i.e. focal therapy, surgery, chemotherapy, radiotherapy, palliative approach (i.e. no intervention)).  &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients that presented following primary treatment given/offered elsewhere.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- All Retinobloastoma patients who were offered/received treatment of any type (i.e. focal therapy, surgery, chemotherapy, radiotherapy,
palliative approach (i.e. no intervention)).

    </Condition>
    <Intervention/>
    <Primary_outcome>To report on the presentation mode of children diagnosed with Rb throughout the world, during 2017, with special attention to intra- versus extraocular disease presentation.  &lt;br/ &gt;&lt;br&gt;Timepoint: 01/01/2017-31/12/2017 data to be collected
    </Primary_outcome>
    <Secondary_outcome>NATimepoint: NA
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Tata Memorial Hospital
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>18/06/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional ethics committee-II, Tata Memorial Hospital. Mumbai
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/11/2018
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>10296435
    </Internal_Number>
    <TrialID>NCT03498482
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Adressing PTSD Symptoms and Aggressive Behavior in Vulnerable Children in Burundi
    </Public_title>
    <Scientific_title>Treating Posttraumatic Stress Disorder and Reducing Aggressive Behavior in Street Children and Vulnerable Children in Burundi Using Narrative Exposure Therapy for Forensic Offender Rehabilitation.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171222
    </Date_registration3>
    <Date_registration>22/12/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03498482
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>8 Years
    </Inclusion_agemin>
    <Inclusion_agemax>20 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 15, 2017
    </Date_enrollement>
    <Target_size>19
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burundi
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of symptoms of posttraumatic stress disorder according to UCLA PTSD&#x0D;&lt;br&gt;             Reaction Index&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Posttraumatic Stress Disorder;Aggressive Behavior
    </Condition>
    <Intervention>Behavioral: Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)
    </Intervention>
    <Primary_outcome>Change of load of traumatic symptoms measured via the UCLA Adolescent PTSD Index (PTSD scale administered by Clinicians)
    </Primary_outcome>
    <Secondary_outcome>Change of number of aggressive acts measured via an adaption of the Domestic and Community Violence Checklist;Change of experienced shame measured via the Shame Variability Questionnaire
    </Secondary_outcome>
    <Secondary_ID>UKCR17
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Vivo international e.V.;Psychologues sans Frontières Burundi;Université Lumière de Bujumbura
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>11636812
    </Internal_Number>
    <TrialID>CTRI/2017/09/009894
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Heat therapy(agnikarma) in Tennis Elbow
    </Public_title>
    <Scientific_title>An Open Label Comparative Clinical Study to assess the Efficacy of Agnikarma in Snayugatavata Treatment Protocol with Agnikarma Alone in Tennis Elbow                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>AMRITA SCHOOL OF AYURVEDA
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170922
    </Date_registration3>
    <Date_registration>22-09-2017
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=16586
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>11-11-2016
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Case Record Numbers  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Dr Lakshmy C Senan
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Amrita School of Ayurveda,Amrita Viswavidyapeetham
Vallikavu, Clappana PO, Kollam, Kerala, India, PIN- 690525 
    </Contact_Address>
    <Contact_Email>drrabi73@gmail.com
    </Contact_Email>
    <Contact_Tel>9567554883
    </Contact_Tel>
    <Contact_Affiliation>AMRITA SCHOOL OF AYURVEDA
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.Patients  selected irrespective of sex, religion, Occupation, socioeconomic status etc &lt;br/ &gt;&lt;br&gt;2.Diagnosis on the basis of signs and symptoms found in Tennis elbow like  &lt;br/ &gt;&lt;br&gt;3.Pain on the outer side of the elbow jt.  &lt;br/ &gt;&lt;br&gt;4.Radiation of pain from elbow to forearm or hand.  &lt;br/ &gt;&lt;br&gt;5.Tenderness over the lateral epicondyle  &lt;br/ &gt;&lt;br&gt;6.Weak grip so that there is Inability to do daily routine work  &lt;br/ &gt;&lt;br&gt;7.Pricking sensation  &lt;br/ &gt;&lt;br&gt;8.Cozenâ??s test positive[13] &lt;br/ &gt;&lt;br&gt;9.Millâ??s maneuver positive[14] &lt;br/ &gt;&lt;br&gt;10.Patient who are willing to undergo trial, are only registered.  &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria:  &lt;br/ &gt;&lt;br&gt;1.Patients not willing to undergo trial.  &lt;br/ &gt;&lt;br&gt;2.Patients below 20 years and above 60 years of age. &lt;br/ &gt;&lt;br&gt;3.Pregnant women. &lt;br/ &gt;&lt;br&gt;4.Patients having joint disorders (viz. RA, OA, GA of elbow joint), Tuberculosis, Diabetes or having associated some other constitutional disorders etc &lt;br/ &gt;&lt;br&gt;5.Malignant tumors, senile osteoporosis etc in and around the elbow region. &lt;br/ &gt;&lt;br&gt;6.Patients associated with Golferâ??s elbow, Olecranon bursitis, Radial tunnel syndrome etc. &lt;br/ &gt;&lt;br&gt;7.Patients with history of compound fracture, Pathological fracture, non united fracture and mal-united fracture of complaining limb  &lt;br/ &gt;&lt;br&gt;8.Agnikarma anarhas &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- tennis elbow patients

    </Condition>
    <Intervention>Intervention1: thermal cauterization&lt;br&gt;: 1.AGNIKARMA(thermal cauterization/ application of heat energy over the specific site)&lt;br&gt;&lt;br&gt;&lt;br&gt;Control Intervention1: upanaha,pichu,agnikarma: 1. upanaha-12 hourly bandage with hot medicated paste of kottamchukkadichoorna, kottamchukkadi taila, saindhava and dhanyamla&lt;br&gt;&lt;br&gt;2.pichu- oil applied over cotton in a localized area&lt;br&gt;&lt;br&gt;3. agnikarma-(thermal cauterization/ application of heat energy over the specific site)&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>1.Pain on the outer side of the elbow joint assessed by Visual Analogue Scale.  &lt;br/ &gt;&lt;br&gt;2. Radiation of pain towards forearm or hand.  &lt;br/ &gt;&lt;br&gt;3. Restricted range of movements. &lt;br/ &gt;&lt;br&gt;4. Pricking sensation  &lt;br/ &gt;&lt;br&gt; &lt;br/ &gt;&lt;br&gt; OBJECTIVE CRITERIA: &lt;br/ &gt;&lt;br&gt;1. Tenderness over the lateral epicondyle &lt;br/ &gt;&lt;br&gt;2. Cozenâ??s test positive &lt;br/ &gt;&lt;br&gt;3. Millâ??s maneuver positive &lt;br/ &gt;&lt;br&gt;Timepoint: Periodic observation will be done on 0th day, 8th day, 15 th, 30 th, and 90 th day.
    </Primary_outcome>
    <Secondary_outcome>recurrenceTimepoint: within 90 days
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Amrita School OF Ayurveda,
Amrita Vishwa Vidyapeetam,
Vallikavu,
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>20/06/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Amrita Institute of Medical Science-Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>8681476
    </Internal_Number>
    <TrialID>ISRCTN89017827
    </TrialID>
    <Last_Refreshed_on>6 January 2020
    </Last_Refreshed_on>
    <Public_title>Wasting and stunting in young children in developing countries
    </Public_title>
    <Scientific_title>Children who are both wasted and stunted are also underweight and have a high risk of death – policy implications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Emergency Nutrition Network
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170821
    </Date_registration3>
    <Date_registration>21/08/2017
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN89017827
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/1992
    </Date_enrollement>
    <Target_size>1796991
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational cross-sectional study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;American Samoa;Angola;Bahrain;Bangladesh;Benin;Burkina Faso;Burundi;Cambodia;Cameroon;Cape Verde;Central African Republic;Chad;Congo;Congo, Democratic Republic;Cote d'Ivoire;Djibouti;Ecuador;Equatorial Guinea;Eritrea;Ethiopia;Gabon;Gambia;Ghana;Guinea-Bissau;Haiti;India;Indonesia;Kenya;Laos;Lesotho;Liberia;Madagascar;Malawi;Mali;Mauritania;Mozambique;Myanmar;Namibia;Nepal;Niger;Nigeria;Pakistan;Rwanda;Senegal;Sierra Leone;Somalia;South Sudan;Sudan;Tajikistan;Tanzania;Timor-Leste;Uganda;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. 6-59 month old children&lt;br&gt;                2. Males and females&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Children over 59 months of age
    </Exclusion_Criteria>
    <Condition>Nutrition &lt;br&gt;Nutritional, Metabolic, Endocrine
    </Condition>
    <Intervention>A database of cross-sectional survey datasets containing data for almost 1.8 million children was compiled. This was analysed to determine the intersection between sets of wasted, stunted, and underweight children; the association between being wasted and being stunted; the severity of wasting and stunting in WaSt children; and the prevalence of WaSt by age and sex. An additional analysis of the WHO Growth Standards sought the maximum possible weight-for-age z-score for WaSt children.
    </Intervention>
    <Primary_outcome>Overlap between wasted, stunted and underweight children as measured by &lt;-2SD WHZ, HAZ, WAZ
    </Primary_outcome>
    <Secondary_outcome>Degree of concurrence i.e. &lt;-2SDWHZ AND ,-2SDHAZ in children and by age (6-59 months) and by sex (male/female) 
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>United States Agency for International Development, 295 Grant Number: ENN AID-OFDA-G-15-00190 , Irish Aid
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>This is an observational study so does not need ethical approval. All data was anonymous and was secondary and readily available for further analysis. There were no human or animal subjects.
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/12/2015
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>10279002
    </Internal_Number>
    <TrialID>NCT03231449
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa
    </Public_title>
    <Scientific_title>A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa
    </Scientific_title>
    <Acronym>FEVRIER
    </Acronym>
    <Primary_sponsor>Cardiologie et Développement
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170721
    </Date_registration3>
    <Date_registration>21/07/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03231449
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2017
    </Date_enrollement>
    <Target_size>5000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Benin;Burkina Faso;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Côte D'Ivoire;Gabon;Guinea;Mozambique;Niger;Senegal;Sudan;Benin;Burkina Faso;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Côte D'Ivoire;Gabon;Guinea;Mozambique;Niger;Senegal;Sudan
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Xavier Jouven, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>cardiologie et Developpement
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  to be hospitalized in a cardiology department of a participating center during the&#x0D;&lt;br&gt;             month of February&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  refusal&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Acute Coronary Syndrome;Heart Failure;Syncope;Stroke;Pericarditis;Endocarditis;Conduction Abnormalities;Rhythm; Abnormal;Pulmonary Embolism;Deep Vein Thrombosis;Other Cardiovascular Conditions
    </Condition>
    <Intervention>Other: observation of current care
    </Intervention>
    <Primary_outcome>Description of patients in cardiology unit in sub-Saharan Africa:socio-demographic characterization;Description of patients in cardiology unit in sub-Saharan Africa:causes of hospitalization;Description of patients in cardiology unit in sub-Saharan Africa: co-morbidities;Description of patients in cardiology unit in sub-Saharan Africa: hospital examinations;Description of patients in cardiology unit in sub-Saharan Africa: duration of hospitalization;Description of patients in cardiology unit in sub-Saharan Africa: discharge diagnosis
    </Primary_outcome>
    <Secondary_outcome>number of patients with heart failure;number of patients with myocardial infarction;number of patients with atrial fibrillation
    </Secondary_outcome>
    <Secondary_ID>001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de la Santé Et de la Recherche Médicale, France
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>6672945
    </Internal_Number>
    <TrialID>NCT03044899
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>African Surgical Outcomes Study (ASOS)
    </Public_title>
    <Scientific_title>African Surgical Outcomes Study (ASOS): An African, Multi-centre Seven Day Evaluation of Patient Care and Clinical Outcomes for Patients Undergoing Surgery
    </Scientific_title>
    <Acronym>ASOS
    </Acronym>
    <Primary_sponsor>University of KwaZulu
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170203
    </Date_registration3>
    <Date_registration>03/02/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03044899
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2016
    </Date_enrollement>
    <Target_size>11422
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase>N/A
    </Phase>
    <Countries>Algeria;Benin;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Nigeria;Niger;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Niger;Nigeria;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Nigeria;Niger;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Niger;Nigeria;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Nigeria;Niger;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Niger;Nigeria;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Nigeria;Niger;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Niger;Nigeria;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Nigeria;Niger;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Niger;Nigeria;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Bruce Biccard, MD, PhD;Bruce Biccard, MD, PhD;Bruce Biccard, MD, PhD;Bruce Biccard, MD, PhD;Bruce Biccard, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>University of KwaZulu;University of KwaZulu;University of KwaZulu;University of KwaZulu;University of KwaZulu
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All consecutive patients admitted to participating centres undergoing elective and&#x0D;&lt;br&gt;             non-elective surgery commencing during a seven day study cohort period with a planned&#x0D;&lt;br&gt;             overnight hospital stay following surgery. The recruitment week will run between&#x0D;&lt;br&gt;             February and May 2016.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients undergoing planned day-case surgery or radiological procedures not requiring&#x0D;&lt;br&gt;             anaesthesia.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All consecutive patients admitted to participating centres undergoing elective and&#x0D;&lt;br&gt;             non-elective surgery commencing during a seven day study cohort period with a planned&#x0D;&lt;br&gt;             overnight hospital stay following surgery. The recruitment week will run between&#x0D;&lt;br&gt;             February and May 2016.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients undergoing planned day-case surgery or radiological procedures not requiring&#x0D;&lt;br&gt;             anaesthesia.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All consecutive patients admitted to participating centres undergoing elective and&#x0D;&lt;br&gt;             non-elective surgery commencing during a seven day study cohort period with a planned&#x0D;&lt;br&gt;             overnight hospital stay following surgery. The recruitment week will run between&#x0D;&lt;br&gt;             February and May 2016.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients undergoing planned day-case surgery or radiological procedures not requiring&#x0D;&lt;br&gt;             anaesthesia.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All consecutive patients admitted to participating centres undergoing elective and&#x0D;&lt;br&gt;             non-elective surgery commencing during a seven day study cohort period with a planned&#x0D;&lt;br&gt;             overnight hospital stay following surgery. The recruitment week will run between&#x0D;&lt;br&gt;             February and May 2016.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients undergoing planned day-case surgery or radiological procedures not requiring&#x0D;&lt;br&gt;             anaesthesia.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Surgery;Surgery- Complications;Mortality;Surgery;Surgery- Complications;Mortality;Surgery;Surgery- Complications;Mortality;Surgery;Surgery- Complications;Mortality
    </Condition>
    <Intervention>Procedure: All surgeries in adult patients;Procedure: All surgeries in adult patients;Procedure: All surgeries in adult patients;Procedure: All surgeries in adult patients
    </Intervention>
    <Primary_outcome>Incidence of in-hospital postoperative complications in adult surgical patients in Africa;Incidence of in-hospital postoperative complications in adult surgical patients in Africa;Incidence of in-hospital postoperative complications in adult surgical patients in Africa
    </Primary_outcome>
    <Secondary_outcome>Rate of mortality on the day of surgery for patients undergoing surgery in Africa;The in-hospital mortality rate for patients undergoing surgery in Africa
    </Secondary_outcome>
    <Secondary_ID>ASOS
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medical Research Council, South Africa
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>8764622
    </Internal_Number>
    <TrialID>ACTRN12616001006437
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>Efficacy and safety  of artemisinin-based combinations: artesunate+amodiaquine and artemether+lumefantrine for the treatment of uncomplicated Plasmodium falciparum in the sites of BUHIGA, KAZIRABAGENI  and KIGOBE   MUTOYI in KARUZI , MAKAMBA, BUJUMBURA MAIRIE et  GITEGA provinces, respectively, BURUNDI
    </Public_title>
    <Scientific_title>Efficacy and safety  of artemisinin-based combinations: artesunate+amodiaquine and artemether+lumefantrine for the treatment of uncomplicated Plasmodium falciparum in the sites of BUHIGA, KAZIRABAGENI  and KIGOBE   MUTOYI in KARUZI , MAKAMBA, BUJUMBURA MAIRIE et  GITEGA provinces, respectively, BURUNDI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Ministry of Health of Burundi
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160729
    </Date_registration3>
    <Date_registration>29/07/2016
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12616001006437.aspx
    </web_address>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>120 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>29/07/2016
    </Date_enrollement>
    <Target_size>528
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Other;Type of endpoint: Safety/efficacy;
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Burundi
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: 1. age between 6 and 120 months;&#x0D;&lt;br&gt;2. mono-infection with P. falciparum detected by microscopy;&#x0D;&lt;br&gt;3. parasitaemia of 1000 - 200000/mocroliter asexual forms;&#x0D;&lt;br&gt;4. presence of axillary temperature greater than or equal 37.5 degrees or history of fever during the past 24 h;&#x0D;&lt;br&gt;5. ability to swallow oral medication;&#x0D;&lt;br&gt;6. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; &#x0D;&lt;br&gt;7. informed consent from the parent or guardian;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1);&#x0D;&lt;br&gt;2. weight under 5 kg;&#x0D;&lt;br&gt;3. mixed or mono-infection with another Plasmodium species detected by microscopy;&#x0D;&lt;br&gt;4. presence of severe malnutrition (defined as a child aged 6-60 months who has a mid-upper arm circumference &lt; 115 mm);&#x0D;&lt;br&gt;5. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);&#x0D;&lt;br&gt;6. regular medication, which may interfere with antimalarial pharmacokinetics;&#x0D;&lt;br&gt;7. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Malaria; &lt;br&gt;Malaria;Infection - Studies of infection and infectious agents
    </Condition>
    <Intervention>To assess the efficacy and safety of artesunate+amodiaquine (artesunate 4 mg/kg body weight + amodiaquine 10mg/kg body weight once daily for 3 consecutive days) and artemether+lumefantrine (20 mg artemether and 120 mg lumefantrine in a tablet) for the treatment of uncomplicated P. falciparum infection. The doses of artemether+lumefantrine is based on weight bands: one tablet to those weighing 5-14kg; two tablets for 15-24 kg; three tablets for 25-34 kg and four tablets for greater than or equal to 35 kg; once daily for 3 consecutive days.. The treatment will be taken orally under direct supervision by the health worker. These two artemisinin-based combinations will be tested separately. The patient will be given either artesunate+amodiaquine or artemether+lumefantrine. Artesunate+amodaiquine will tested in all sites while artemether+lumefantrine will evaluated in two sites. Eligible subjects will be treated for three days and followed up for 28 days.
    </Intervention>
    <Primary_outcome>Percent of treatment failures (early treatment failure + late clinical failure +late parasitological failure). This is composite primary outcome.&lt;br&gt;&lt;br&gt;Enrolled patients will be assessed for parasitological (using microscopy) and clinical responses during the 28 days follow-up and treatment outcomes will be classified according to the latest WHO protocol.[At day 28 following initiation of treatments]
    </Primary_outcome>
    <Secondary_outcome>Percent of adverse event will be documented. &#x0D;&lt;br&gt;The known adverse events of:&#x0D;&lt;br&gt;a. artesunate+amodiaquine are abdominal pain, asthenia, cough, diarrhoea, dizziness, insomnia, loss of appetite, nausea, vomiting.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;b. artemether+lumefantrine are abdominal pain, asthenia, cough, diarrhoea, dizziness, fever, headache, joint and muscle pain, loss of appetite, rush, nausea, vomiting.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Parents or guardians of all enrolled patients will be asked routinely about previous symptoms and about symptoms that have emerged since the previous follow-up visit. When clinically indicated, patients will be evaluated and treated appropriately. All adverse events will be recorded on the case report form.[At day 28 following initiation of treatments];Prevalence of artemisinin resistance molecular markers (K13).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Parasite DNA extracted from the dried blood spots will be analyzed by PCR and sequencing for the presence of K13 (molecular marker for artemisinin resistance).[At day 0 (prior initiation of treatment)]
    </Secondary_outcome>
    <Secondary_ID>Nil
    </Secondary_ID>
    <Source_Support>Ministry of Health of Burundi
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>WHO ethics and research committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>5843509
    </Internal_Number>
    <TrialID>ISRCTN37820075
    </TrialID>
    <Last_Refreshed_on>7 November 2016
    </Last_Refreshed_on>
    <Public_title>An efficacy study of sociotherapy group intervention in the Sexual Reproductive Health and Rights (SRHR) program in Burundi
    </Public_title>
    <Scientific_title>A Naturalistic Cluster Randomized Trial to study the efficacy of socio therapy group intervention in the SRHR program in Burundi                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Dutch Embassy Burundi
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160527
    </Date_registration3>
    <Date_registration>27/05/2016
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN37820075
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>25/03/2016
    </Date_enrollement>
    <Target_size>450
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Naturalistic cluster randomized trial (Treatment)
    </Study_design>
    <Phase/>
    <Countries>Burundi
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 16 years and older&lt;br&gt;2. Sexual Reproductive Health and Rights (SRHR) -related problems
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Those who require immediate medical treatment.
    </Exclusion_Criteria>
    <Condition>The negative consequences of violations of Sexual Reproductive Health and Rights (SRHR) on mental health, well-being and social functioning. &lt;br&gt;Mental and Behavioural Disorders &lt;br&gt;Mental wellbeing
    </Condition>
    <Intervention>The study will be conducted in different collines (villiages) in 7 communes spread over three provinces: Bujumbura Rural, Bubanza and Cibitoke. To avoid contamination of the intervention 15 collines (villiages) in these 7 communes are randomly allocated to the sociotherapy groups or control groups.&lt;br&gt;&lt;br&gt;Intervention group: Participants attend a course of 15 group sessions of the Sociotherapy Intervention (ST) over a period of 8 weeks. These sessions are guided by trained facilitators and involve group discussions, role playing, practicing the Johari window, the square of autonomy and the four-circle model about culture in new environments technique, implementing insights about types of families, socialization, social systems, and social identity, listening and relaying the message, games and their importance, fundamental needs, emotions, the way to act in a new environment, communicating by signs (without words) and on prejudices.&lt;br&gt;These 15 sessions intervention consist of 6 phases with their own objectives to reach: &lt;br&gt;1. Security/peace&lt;br&gt;2. Confidence/trust&lt;br&gt;3. Mutual care and assistance&lt;br&gt;4. Mutual respect&lt;br&gt;5. New norms&lt;br&gt;6. Discussing the experienced change by reflecting the past and present situation. &lt;br&gt;All these objectives cover the following themes: &lt;br&gt;1. Having a desire/thirst to care for each other&lt;br&gt;2. Equality among the participants&lt;br&gt;3. Democracy during the sessions&lt;br&gt;4. Responsibility for the group process&lt;br&gt;5. Full participation&lt;br&gt;6. A focus on here, now and the future&lt;br&gt;7. Learning by doing to obtain and maintain change.  &lt;br&gt;&lt;br&gt;Control group: Participants are placed on a waiting list for the duration of the study. After the study they will be offered the opportunity to undergo the sociotherapeutic intervention.&lt;br&gt;&lt;br&gt;Participants in both groups are followed up after 8 and 15 weeks
    </Intervention>
    <Primary_outcome>1. Mental Health is measured using the five-item version of the Mental Health Inventory (MHI) at baseline, 8 and 15 weeks&lt;br&gt;2. Social Wellbeing is measured using the Subjective Wellbeing scale (SW-4) at baseline, 8 and 15 weeks&lt;br&gt;3. Social functioning is measured using the RAND SF-12 at baseline, 8 and 15 weeks
    </Primary_outcome>
    <Secondary_outcome>1. General Health complaints are measured using the SCL-90-R (items 1, 4, 12, 27, 42, 52, 56) at baseline, 8 and 15 weeks&lt;br&gt;2. Societal changes are measured at baseline, 8 and 15 weeks using:&lt;br&gt;2.1. The Sense of community index&lt;br&gt;2.2. The Sense of coherence scale (SOC-13)
    </Secondary_outcome>
    <Secondary_ID> N/A
    </Secondary_ID>
    <Source_Support>Dutch Embassy Burundi
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>10901610
    </Internal_Number>
    <TrialID>NCT02626286
    </TrialID>
    <Last_Refreshed_on>3 May 2021
    </Last_Refreshed_on>
    <Public_title>Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa
    </Public_title>
    <Scientific_title>Prevention of HIV Infection in Men Who Have Sex With Men in Sub-Saharan Africa: Feasibility and Interest of a Quarterly Preventive Global Care (CohMSM)
    </Scientific_title>
    <Acronym>CohMSM
    </Acronym>
    <Primary_sponsor>ANRS, Emerging Infectious Diseases
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20151120
    </Date_registration3>
    <Date_registration>20/11/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02626286
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>June 2015
    </Date_enrollement>
    <Target_size>885
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burkina Faso;Côte D'Ivoire;Mali;Togo;Burkina Faso;Côte D'Ivoire;Mali;Togo;Burundi
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Man over 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Reporting at least one anal sex (passive or active) with another man within the last&#x0D;&lt;br&gt;             three months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to reach the local site of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agreeing to participate in the study and signing the informed consent form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of antiretroviral therapy (except for pre- or post-exposure prophylaxis)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another biomedical or behavioral research on HIV or sexually&#x0D;&lt;br&gt;             transmitted infections&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Impairment of the person making his participation in the study, or information&#x0D;&lt;br&gt;             understanding, difficult or impossible&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Predictable protocol violation (geographical distance or other reasons)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infection
    </Condition>
    <Intervention>Other: HIV quarterly global care
    </Intervention>
    <Primary_outcome>Number of people followed after 3 years compared to the number of persons included (retention in the program);Percentage of performed visits/scheduled visits;Percentage of performed tests/scheduled tests;Incidence of sexually transmitted infections;Number of unprotected anal sex;Antiretroviral therapy initiation probability in HIV-positive MSM;Antiretroviral therapy maintenance probability in HIV-positive MSM;Percentage of antiretroviral therapy observance in HIV-positive MSM;Percentage of HIV-positive MSM with viral load&gt;1000 copies/mL;Percentage of HIV-positive MSM with CD4=reference (or CD4&lt;100/mm3);Percentage of HIV-positive MSM with new or recurrent AIDS-defining events (clinical stage 4);Percentage of HIV-positive MSM died under antiretroviral therapy;Percentage of HIV-positive MSM with detectable viral load and inconsistent condom use with a partner seronegative or with unknown HIV status;Number of HIV subtypes / circulating recombinant forms;Number of co-infections with several viral variants;Number of transmitted and acquired resistance mutations;Number of male sex partners
    </Primary_outcome>
    <Secondary_ID>ANRS 12324 CohMSM
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Expertise France;Université Montpellier;IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille);Coalition Internationale Sida;ARCAD-SIDA MALI;Espace Confiance, Côte d'Ivoire;Programme PAC-CI, Abidjan, Côte d'Ivoire;Association African Solidarité;Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso;Espoir Vie-Togo - ONG
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>6649125
    </Internal_Number>
    <TrialID>NCT02503488
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Decreasing Youth Involvement in Violence in Burundi
    </Public_title>
    <Scientific_title>Decreasing Youth Involvement in Violence in Burundi
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150630
    </Date_registration3>
    <Date_registration>30/06/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02503488
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>40 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 2015
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burundi;Burundi;Burundi;Burundi;Burundi
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Anselm Crombach;Anselm Crombach;Anselm Crombach;Anselm Crombach;Anselm Crombach
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>University of Konstanz, vivo international e.V., Psychologues sans Frontiers Burundi;University of Konstanz, vivo international e.V., Psychologues sans Frontiers Burundi;University of Konstanz, vivo international e.V., Psychologues sans Frontiers Burundi;University of Konstanz, vivo international e.V., Psychologues sans Frontiers Burundi;University of Konstanz, vivo international e.V., Psychologues sans Frontiers Burundi
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of symptoms of posttraumatic stress disorder according to the&#x0D;&lt;br&gt;             Posttraumatic Symptom Scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of appetitive aggression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Violent behavior during the past three months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of mind altering drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of symptoms of posttraumatic stress disorder according to the&#x0D;&lt;br&gt;             Posttraumatic Symptom Scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of appetitive aggression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Violent behavior during the past three months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of mind altering drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of symptoms of posttraumatic stress disorder according to the&#x0D;&lt;br&gt;             Posttraumatic Symptom Scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of appetitive aggression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Violent behavior during the past three months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of mind altering drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of symptoms of posttraumatic stress disorder according to the&#x0D;&lt;br&gt;             Posttraumatic Symptom Scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of appetitive aggression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Violent behavior during the past three months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of mind altering drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Posttraumatic Stress Disorder;Depression;Aggression;Posttraumatic Stress Disorder;Depression;Aggression;Posttraumatic Stress Disorder;Depression;Aggression;Posttraumatic Stress Disorder;Depression;Aggression
    </Condition>
    <Intervention>Behavioral: Narrative Exposure Therapy for Forensic Offender Rehab;Behavioral: Treatment as Usual;Behavioral: Narrative Exposure Therapy for Forensic Offender Rehab;Behavioral: Treatment as Usual;Behavioral: Narrative Exposure Therapy for Forensic Offender Rehab;Behavioral: Treatment as Usual;Behavioral: Narrative Exposure Therapy for Forensic Offender Rehab;Behavioral: Treatment as Usual
    </Intervention>
    <Primary_outcome>Change in Baseline PTSD Scores at 3-months-followup and 9-months-followup;Change in Baseline Depression Scores at 3-months-followup and 9-months-followup;Change in Baseline Appetitive Aggression Scores at 3-months-followup and 9-months-followup;Change in Baseline PTSD Scores at 3-months-followup and 9-months-followup;Change in Baseline Depression Scores at 3-months-followup and 9-months-followup;Change in Baseline Appetitive Aggression Scores at 3-months-followup and 9-months-followup;Change in Baseline PTSD Scores at 3-months-followup and 9-months-followup;Change in Baseline Depression Scores at 3-months-followup and 9-months-followup;Change in Baseline Appetitive Aggression Scores at 3-months-followup and 9-months-followup
    </Primary_outcome>
    <Secondary_outcome>Change in Baseline Physical State at 3-months-followup and 9-months-followup;Change in Social Integration Scores at 3-months-followup and 9-months-followup;Change in Scores on the Attitudes Toward Members of Other Political Parties Scale at 3-months-followup and 9-months-followup
    </Secondary_outcome>
    <Secondary_ID>UKonstanz
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Vivo international e.V.;Action on Armed Violence;Psychologues sans Frontières Burundi
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>8762273
    </Internal_Number>
    <TrialID>ACTRN12615000106538
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>Efficacy and safety of artemisinin-based combination therapy: artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) in the treatment of uncomplicated falciparum malaria in 4 provinces of Burundi
    </Public_title>
    <Scientific_title>Efficacy and safety of artemisinin-based combination therapy: artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) in the treatment of uncomplicated falciparum malaria in 4 provinces of Burundi                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Ministry of Public Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150205
    </Date_registration3>
    <Date_registration>05/02/2015
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12615000106538.aspx
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>10 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>15/02/2015
    </Date_enrollement>
    <Target_size>528
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase>Not Applicable
    </Phase>
    <Countries>Burundi
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: children aged 6 months to 10 years&#x0D;&lt;br&gt;monoinfection with P falciparum confirmed by microscopy&#x0D;&lt;br&gt;parasitemia between 1000-200000 parasites (asexual) per microliter&#x0D;&lt;br&gt;fever (equal or greater than 37.5 celsius) or history of fever within past 24 hours&#x0D;&lt;br&gt;able to swallow oral medication &#x0D;&lt;br&gt;ability and willingness to follow protocol procedures and schedule of assessments&#x0D;&lt;br&gt;written informed consent from parent or guardian
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: presence of danger and signs of severe malaria&#x0D;&lt;br&gt;mixed infection or infection of than P. falciparum detected by microscopy&#x0D;&lt;br&gt;severely malnourished&#x0D;&lt;br&gt;fever due to other diseases (measles, acute lower respiratory tract infection, severa diarrhea); chronic or severe hepatic, renal or cardiac diseases; HIV/AIDS&#x0D;&lt;br&gt;clinical signs of acute jaundice&#x0D;&lt;br&gt;abnormal level of granulocytes or liver transaminases&#x0D;&lt;br&gt;regular medication that could interfere with antimalarial pharmacokinetics;&#x0D;&lt;br&gt;history of hypersensitivity reactions or contraindications to any medicines being used&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Uncomplicated falciparum malaria; &lt;br&gt;Uncomplicated falciparum malaria;Infection - Other infectious diseases
    </Condition>
    <Intervention>Patients with confirmed falciparum malaria from 4 provinces of Burundi (Bujumbura, Makamba, Karuzi and Gitega) will be treated  with artesunate (4mg/kg)-amodiaquine (10 mg/kg) once daily for three days and will be followed for up to 28 days with fixed scheduled clinical and parasitological assessements.  Three formulations of fixed combination tablets of artesunate-amodiaquine will be used: 25/67.5 mg; 50/135mg and 100/270 mg). Number of tablet(s) to be adminsitered is based on body weight according to the national policy.  Once the target number of patients have been enrolled, a second cohort will be treated with artemether (4 mg/kg)-lumefantrine 25 mg/kg) given in two daily doses for three days and will be followed for up to 28 days with fixed scheduled clinical and parasitological assessements.  Fixed combination tablet containing 20 mg artemether and 120 mg lumefantrine will be used: the number of tablets to be administered for the morning and evening dose is based on body weight according to the national policy.  All doses for both treatments will be administered under supervsion of medical staff.
    </Intervention>
    <Primary_outcome>proportion of patients with PCR-corrected adequate clinical and parasitological response according to WHO criteria [Day 28]
    </Primary_outcome>
    <Secondary_outcome>Incidence of adverse events. Known or possible adverse events associated with ASAQ include anorexia, abdominal pain, nausea, fatique, drowziness, dizziness, insomnia and cough.  Known or possible adverse events associated to AL include fever, cough, vomiting, anorexia and headache[Day 28]
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Ministry of Health
    </Source_Support>
    <Secondary_Sponsor>World Health Organisation;The Global Funds to Fight AIDS,TB  and MALARIA
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethics Research Committee, World Health Organisation
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>6640028
    </Internal_Number>
    <TrialID>NCT02242136
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Treatment of Posttraumatic Stress Disorder and Aggressive Behavior in Soldiers and Ex-combatants
    </Public_title>
    <Scientific_title>Formation, Orientation and Rehabilitation by Means of Narrative Exposure Therapy (FORNET) for Returning Soldiers of the African Union Mission to Somalia, Male and Female Ex-combatants in Burundi
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140914
    </Date_registration3>
    <Date_registration>14/09/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02242136
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2014
    </Date_enrollement>
    <Target_size>56
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burundi;Burundi;Burundi;Burundi;Burundi
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Anselm Crombach, Dr.;Anselm Crombach, Dr.;Anselm Crombach, Dr.;Anselm Crombach, Dr.;Anselm Crombach, Dr.
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>University of Konstanz;University of Konstanz;University of Konstanz;University of Konstanz;University of Konstanz
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of symptoms of posttraumatic stress disorder according to the&#x0D;&lt;br&gt;             Posttraumatic Symptom Scale,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of appetitive aggression,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Violent behavior during the past three months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of mind altering drugs,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of symptoms of posttraumatic stress disorder according to the&#x0D;&lt;br&gt;             Posttraumatic Symptom Scale,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of appetitive aggression,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Violent behavior during the past three months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of mind altering drugs,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of symptoms of posttraumatic stress disorder according to the&#x0D;&lt;br&gt;             Posttraumatic Symptom Scale,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of appetitive aggression,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Violent behavior during the past three months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of mind altering drugs,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of symptoms of posttraumatic stress disorder according to the&#x0D;&lt;br&gt;             Posttraumatic Symptom Scale,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High degree of appetitive aggression,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Violent behavior during the past three months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of mind altering drugs,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Posttraumatic Stress Disorder;Aggressive Behavior;Appetitive Aggression;Posttraumatic Stress Disorder;Aggressive Behavior;Appetitive Aggression;Posttraumatic Stress Disorder;Aggressive Behavior;Appetitive Aggression;Posttraumatic Stress Disorder;Aggressive Behavior;Appetitive Aggression
    </Condition>
    <Intervention>Behavioral: FORNET;Behavioral: FORNET;Behavioral: FORNET;Behavioral: FORNET
    </Intervention>
    <Primary_outcome>Change in Diagnosis and load of PTSD symptoms assessed via the Posttraumatic Symptom Scale - Interview (PSS-I);Change from baseline in the extend of appetitive aggression assessed via the Appetitive Aggression Scale (AAS);Change in number of committed violent acts during the past three months assessed via the Domestic and Community Violence Checklist (DCVC);Change in Diagnosis and load of PTSD symptoms assessed via the Posttraumatic Symptom Scale - Interview (PSS-I);Change from baseline in the extend of appetitive aggression assessed via the Appetitive Aggression Scale (AAS);Change in number of committed violent acts during the past three months assessed via the Domestic and Community Violence Checklist (DCVC);Change in Diagnosis and load of PTSD symptoms assessed via the Posttraumatic Symptom Scale - Interview (PSS-I);Change from baseline in the extend of appetitive aggression assessed via the Appetitive Aggression Scale (AAS);Change in number of committed violent acts during the past three months assessed via the Domestic and Community Violence Checklist (DCVC)
    </Primary_outcome>
    <Secondary_outcome>Change from baseline in load of depressive symptoms assessed via the Patient Health Questionnaire-9 (PHQ-9);Change in strength of suicidal ideation measured via the Mini International Neuropsychiatric Interview (M.I.N.I.);Change in physical health complains
    </Secondary_outcome>
    <Secondary_ID>UKULBU2014
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Université Lumière de Bujumbura;The Volkswagen Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>5014354
    </Internal_Number>
    <TrialID>NCT02172066
    </TrialID>
    <Last_Refreshed_on>3 August 2015
    </Last_Refreshed_on>
    <Public_title>Narrative Exposure Therapy (NET) for Victims of the Recent Flood Disaster in Burundi
    </Public_title>
    <Scientific_title>Evaluation of the Narrative Exposure Therapy (NET) as Means to Reduce Psychological Impairment in the Aftermath of the Recent Flood Disaster in Bujumbura, Burundi
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140619
    </Date_registration3>
    <Date_registration>19/06/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02172066
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>June 2014
    </Date_enrollement>
    <Target_size>51
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burundi
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Anselm Crombach, Dr
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Konstanz
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals severely affected (e.g., who had lost their children) by the flood&#x0D;&lt;br&gt;             disaster in Bujumbura&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All participants were part of the emergency program of the Red Cross Burundi who&#x0D;&lt;br&gt;             assisted those most affected by the flood disaster in Bujumbura&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inclusion criteria for therapy: High degree of symptoms of posttraumatic stress&#x0D;&lt;br&gt;             disorder according to the Posttraumatic Symptom Scale - Interview (PSSI)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current substance dependence&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Posttraumatic Stress Disorder
    </Condition>
    <Intervention>Behavioral: Narrative Exposure Therapy (NET)
    </Intervention>
    <Primary_outcome>Change from baseline in Diagnosis and load of PTSD symptoms assessed via the Posttraumatic Symptom Scale - Interview (PSS-I) at 3 and 9 months follow-up
    </Primary_outcome>
    <Secondary_outcome>Change from baseline in load of depressive symptoms assessed via the Patient Health Questionnaire-9 (PHQ-9) at 3 months and 9 months follow-up;Change in strength of suicidal ideation measured via the Mini International Neuropsychiatric Interview (M.I.N.I.) at 3 months and 6 months follow-up
    </Secondary_outcome>
    <Secondary_ID>UKCR2014
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>vivo international e.V.;University Lumière of Bujumbura, Burundi
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>4965277
    </Internal_Number>
    <TrialID>NCT01729325
    </TrialID>
    <Last_Refreshed_on>29 June 2015
    </Last_Refreshed_on>
    <Public_title>Prevention of Post-Traumatic Stress Disorder in Soldiers
    </Public_title>
    <Scientific_title>Prevention of Post-Traumatic Stress Disorder in Relation to Appetitive Aggression in Burundian Soldiers Deployed in a Peace-keeping Mission in Somalia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20121113
    </Date_registration3>
    <Date_registration>13/11/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01729325
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>November 2012
    </Date_enrollement>
    <Target_size>118
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Burundi
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exposure to traumatic experiences derived from expert interviews with scores of the&#x0D;&lt;br&gt;             Traumatic Life Event List for War and Torture&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Soldiers are part of the Burundian army and of the joint African Union and United&#x0D;&lt;br&gt;             Nations peacekeeping mission in Somalia (AMISOM)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of mind altering drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychotic symptoms&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Post-traumatic Stress Disorder (PTSD);Aggressive Behavior
    </Condition>
    <Intervention>Behavioral: Preventive Narrative Exposure Therapy
    </Intervention>
    <Primary_outcome>Severity of traumatic symptoms measured via the Post-traumatic Stress Disorder Scale-Interview (PSS-I);Extend of appetitive aggression via the Appetitive Aggressions Scale (AAS)
    </Primary_outcome>
    <Secondary_outcome>Severity of depressive symptoms measured via the Patient Health Questionnaire-9 (PHQ-9);Strength of suicidal ideation measured via the MINI;Physical health complains
    </Secondary_outcome>
    <Secondary_ID>UKULBUSO2012
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Volkswagen Stiftung Germany
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>5672162
    </Internal_Number>
    <TrialID>NCT01715922
    </TrialID>
    <Last_Refreshed_on>8 August 2016
    </Last_Refreshed_on>
    <Public_title>Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa
    </Public_title>
    <Scientific_title>Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Sub-Saharan Africa Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Complemented by Repeat Lumbar Punctures
    </Scientific_title>
    <Acronym>Flucocrypto
    </Acronym>
    <Primary_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20121019
    </Date_registration3>
    <Date_registration>19/10/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01715922
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>May 2012
    </Date_enrollement>
    <Target_size>41
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Burundi;Côte D'Ivoire;Burundi;Côte D'Ivoire
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Olivier Bouchaud, PhD;Théodore Niyangobo, PhD;Amélie Chabrol, MD;Kakou AKA, Professor
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Hopital Avicenne, Service des maladies infectieuses, Paris, france;CHU Kamenge, Bujumbura, Burundi;Hopital Avicenne, Service des maladies infectieuses, Paris, france;CHU Triechville
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  &gt; 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV Infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  First episode of cryptococcal meningitis on basis CSF India ink and/or CSF&#x0D;&lt;br&gt;             cryptococcal antigen.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Glasgow &gt; 9 after lumbar punctures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of peripheral focal deficit in the limbs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  informed consent signed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hemoglobin &lt;7.5 g / dl;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  neutrophils count &lt;500/mm3;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Platelets count &lt;50 000/mm3;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  transaminases &gt; 5 times upper limit of normal;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Troubles with severe mental alertness Glasgow &lt;9 after the initial lumbar puncture;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  focal neurological deficit in the limbs;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or lactation on going;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ongoing systemic antifungal treatment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of cryptococcal meningitis;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ongoing rifampicin and ritonavir treatment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject participating in another study with a risk of mutual interference on the&#x0D;&lt;br&gt;             interpretation of results.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cryptococcal Meningitis;HIV
    </Condition>
    <Intervention>Drug: Fluconazole;Drug: Flucytosine;Procedure: lumbar punctures
    </Intervention>
    <Primary_outcome>Mortality rate
    </Primary_outcome>
    <Secondary_outcome>Mortality rate;Percentage of patients with negative cerebrospinal fluid (CSF) cultures;Number of relapses of cryptococcal throughout the monitoring period;Number of "Immune Reconstitution Inflammatory Syndrome" (IRIS) throughout the monitoring period;Number and severity of adverse events;Cerebrospinal fluid pressure evolution;Percentage of patients with undetectable viral load;CD4 count;Concentration of flucytosine in cerebrospinal fluid;Sensitivity of cryptococcal antigen by strip method LFA (lateral-flow immunoassay);CSF total volume discharged;Number of lumbar punctures performed;Concentration of fluconazole in plasma;Concentration of fluconazole in cerebrospinal fluid;Concentration of flucytosine in plasma;MICs of fluconazole
    </Secondary_outcome>
    <Secondary_ID>ANRS 12257 Flucocrypto
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>CHU Kamenge, BURUNDI;Hospital Avicenne;Institut Pasteur;Hôpital Necker-Enfants Malades;Institut de Médecine et Epidémiologie Appliquée (IMEA);Hôpital de Treichville;Hôpital Cocody
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>4705421
    </Internal_Number>
    <TrialID>NCT01519193
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Treatment of Aggressive Behavior and Post-Traumatic Stress Disorder
    </Public_title>
    <Scientific_title>Treatment of Aggressive Behavior and Post-Traumatic Stress Disorder in Former Street Children and Vulnerable Children in Burundi With Narrative Exposure Therapy for Violent Offenders
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20111201
    </Date_registration3>
    <Date_registration>01/12/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01519193
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Years
    </Inclusion_agemin>
    <Inclusion_agemax>23 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>January 2011
    </Date_enrollement>
    <Target_size>42
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Burundi
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Anselm Crombach, Dipl.-Psych.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Constance
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Positive Emotions concerning aggressive behavior derived from expert interviews with&#x0D;&lt;br&gt;             higher Scores of the Appetitive Aggression Scale (AAS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  children are part of an aid program for reintegration into society&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  current substance dependance or use of antipsychotic drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  chronically ill children&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Aggressive Behavior;Post-Traumatic Stress Disorder
    </Condition>
    <Intervention>Behavioral: Narrative Exposure Therapy for violent offenders (NETvo)
    </Intervention>
    <Primary_outcome>Positive emotions linked to aggressive behavior via the AAS-CS (Appetitive Aggressions Scale for children and students);Load of traumatic symptoms measured via the UCLA Adolescent PTSD Index (Clinician-administered PTSD scale)
    </Primary_outcome>
    <Secondary_outcome>Load of depressive symptoms measured via the MINI-KID;Strength of suicidal ideation measured via the MINI-KID;Functionality measured via the CGAS (Children's Global Assessment Scale) and SDQ (Strengths and Difficulties Questionnaire)
    </Secondary_outcome>
    <Secondary_ID>UKCR2011
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>4690429
    </Internal_Number>
    <TrialID>NCT01322880
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Domestic Violence Discussion Session
    </Public_title>
    <Scientific_title>Microfinance-Discussion Session Intervention in Post-Conflict Central African States
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>London School of Economics and Political Science
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20110324
    </Date_registration3>
    <Date_registration>24/03/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01322880
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>January 2008
    </Date_enrollement>
    <Target_size>598
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burundi
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Radha Iyengar, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>London School of Economics and Political Science
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in Village Savings and Loans Association program administered by&#x0D;&lt;br&gt;             International Rescue Committee--Burundi&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Intimate Partner Violence
    </Condition>
    <Intervention>Behavioral: Discussion sessions;Behavioral: Village Savings and Loans Associations
    </Intervention>
    <Primary_outcome>Domestic Violence Exposure
    </Primary_outcome>
    <Secondary_outcome>Attitudes towards gender roles and rights;Economic Empowerment
    </Secondary_outcome>
    <Secondary_ID>HF15660-101
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>5388862
    </Internal_Number>
    <TrialID>NCT01072279
    </TrialID>
    <Last_Refreshed_on>14 March 2016
    </Last_Refreshed_on>
    <Public_title>Preventing Malnutrition in Children Under Two Years of Age Approach
    </Public_title>
    <Scientific_title>Strengthening and Evaluating the "Preventing Malnutrition in Children Under Two Years of Age Approach" (PM2A) in Guatemala and Burundi
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International Food Policy Research Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20100217
    </Date_registration3>
    <Date_registration>17/02/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01072279
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>42 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>April 2010
    </Date_enrollement>
    <Target_size>16895
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burundi;Guatemala;Burundi;Guatemala
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Marie Ruel, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>IFPRI
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Guatemala: pregnant mothers and subsequently their born children up to the age of 24&#x0D;&lt;br&gt;             months;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Burundi: cross-sectional study: children 0 to 42 of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malnutrition
    </Condition>
    <Intervention>Other: Tubaramure (Burundi);Other: Procomida (Guatemala)
    </Intervention>
    <Primary_outcome>child nutritional status
    </Primary_outcome>
    <Secondary_outcome>household food security;household food and non-food consumption;maternal knowledge on infant and young child feeding (IYCF) and health;attitudes towards IYCF and health;morbidity;health care seeking behavior
    </Secondary_outcome>
    <Secondary_ID>4001-IFPRI-00
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>United States Agency for International Development (USAID);Catholic Relieve Services-Burundi;Mercy Corps-Guatemala;Food and Nutrition Technical Assistance Project 2 of the Academy of Educational Development
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:21:04</Export_date>
    <Internal_Number>5806543
    </Internal_Number>
    <TrialID>ISRCTN42284825
    </TrialID>
    <Last_Refreshed_on>17 October 2016
    </Last_Refreshed_on>
    <Public_title>Efficacy of a school-based psychosocial intervention to deal with the psychosocial impact of armed conflict on school-aged children in Burundi
    </Public_title>
    <Scientific_title>Efficacy of a school-based psychosocial intervention to deal with the psychosocial impact of armed conflict on school-aged children in Burundi                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>HealthNet TPO (The Netherlands)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20060609
    </Date_registration3>
    <Date_registration>09/06/2006
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN42284825
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/05/2006
    </Date_enrollement>
    <Target_size>240
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cluster randomization of schools to intervention (structured school-based psychosocial program) or waitlist condition (receiving treatment after the research) (Treatment)
    </Study_design>
    <Phase>Not Specified
    </Phase>
    <Countries>Burundi
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Children screened for exposure to traumatic events, post-traumatic stress symptoms or depressive anxiety symptoms, with the use of symptom checklists
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Serious psychopathology and psychiatric disorders (mutism, retardation, psychotic symptoms) or incapability to function in a group (conduct disorders, harming others), as judged by local psychosocial counsellors
    </Exclusion_Criteria>
    <Condition>Multiple impact of armed conflict on psychosocial wellbeing (post-traumatic stress disorder) &lt;br&gt;Mental and Behavioural Disorders &lt;br&gt;Post-traumatic stress disorder
    </Condition>
    <Intervention>Classroom-based structured, manualized psychosocial intervention, called the class-room based intervention (CBI), as designed by the Center for Trauma Psychology (Boston, Massachusetts) versus the waitlist condition.&lt;br&gt;The CBI entails a 15-session program that encompasses working with the trauma narrative, creative techniques (drama, music), and specifically designed games. The waitlist condition simply entails the provision of treatment after the research is finished.
    </Intervention>
    <Primary_outcome>Post-traumatic stress disorder (PTSD) and depressive symptoms
    </Primary_outcome>
    <Secondary_outcome>Anxiety, aggression, daily functioning, social support, sociometric measurements (sociogram), coping, family functioning, hope, and school functioning (grades, absenteeism)
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>Plan International
    </Source_Support>
    
  </Trial>
</Trials_downloaded_from_ICTRP>